



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/078, A61K 38/05	A1	(11) International Publication Number: WO 98/12211 (43) International Publication Date: 26 March 1998 (26.03.98)
(21) International Application Number: PCT/US97/13738 (22) International Filing Date: 4 August 1997 (04.08.97) (30) Priority Data: 08/719,291 19 September 1996 (19.09.96) US (71) Applicant: HOECHST MARION ROUSSEL, INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: WARSHAWSKY, Alan, M.; 10713 Shadowcrest Court, Cincinnati, OH 45242 (US). FLYNN, Gary, A.; 9750 N. Cliff View Place, Tucson, AZ 85735 (US). PATEL, Meena, V.; Apartment 3703 Tower 3, 605 West Madison Street, Chicago, IL 60661 (US). BEIGHT, Douglas, W.; Apartment G, 9368 Benchmark Drive, Indianapolis, IN 46240 (US). BURKHART, Joseph, P.; 701 Andrews Boulevard, Plainfield, IN 46168 (US). TSAY, Jiu-Tsair; 7975 Jolain Drive, Cincinnati, OH 45242 (US). JANUSZ, Michael, J.; 1479 Nixon Camp Road, Oregonia, OH 45054 (US). SHEN, Jian; 10842 Lakehurst Court, Cincinnati, OH 45242 (US). DHARANIPRAGADA, Ramalinga, M.; 951 West Orange Grove Road #6102, Tucson, AZ 85704 (US).		(74) Agent: STEMERICK, David, M.; Hoechst Marion Roussel, Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincin- nati, OH 45215-6300 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE (57) Abstract The present invention relates to certain novel 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10

**3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN
DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE**

BACKGROUND OF THE INVENTION

15

The matrix metalloproteinases (MMP's) are a family of zinc containing endopeptidases which are capable of cleaving large biomolecules such as the collagens, proteoglycans and gelatins. Expression is upregulated by pro-inflammatory cytokines and/or growth factors. The MMP's are secreted as inactive zymogens which, upon activation, are subject to control by endogenous inhibitors, for example, tissue inhibitor of metalloproteinases (TIMP) and α_2 -macroglobulin. Chapman, K.T. et al., J. Med. Chem. 36, 4293-4301 (1993); Beckett, R.P. et al., DDT 1, 16-26 (1996). The characterizing feature of diseases involving the enzymes appears to be a stoichiometric imbalance between active enzymes and endogenous inhibitors, leading to excessive tissue disruption, and often degradation. McCachren, S.S., Arthritis Rheum. 34, 1085-1093 (1991).

25

The discovery of different families of matrix metalloproteinase, their relationships, and their individual characteristics have been categorized in several reports. Emonard, H. et al., Cell Molec. Biol. 36, 131-153 (1990); Birkedal-Hansen, H., J. Oral Pathol. 17, 445-451 (1988); Matrisian, L.M., Trends Genet. 6, 121-125 (1990); Murphy, G.J.P. et al., FEBS Lett. 289, 4-7 (1991); Matrisian, L.M., Bioessays 14, 455-463 (1992). Three groups of secreted MMPs have been delineated: the collagenases which have triple helical interstitial collagen as a substrate, the gelatinases which are proteinases of denatured collagen and Type IV collagen, and the stromelysins which were originally characterized as proteoglycanases but have now

30

been identified to have a broader proteolytic spectrum. Examples of specific collagenases include fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), and collagenase 3 (MMP-13). Examples of gelatinases include 72 kDa gelatinase (gelatinase A; MMP-2) and 92 kDa gelatinase (gelatinase B; MMP-9). Examples of stromelysins include stromelysin 1 (MMP-3), stromelysin 2 (MMP-10) and matrilysin (MMP-7). Other MMPs which do not fit neatly into the above groups include metalloelastase (MMP-12), membrane-type MMP (MT-MMP or MMP-14) and stromelysin 3 (MMP-11). Beckett, R.P. et al., supra.

Over-expression and activation of MMPs have been linked with a wide range of diseases such as cancer; rheumatoid arthritis; osteoarthritis; chronic inflammatory disorders, such as emphysema; cardiovascular disorders, such as atherosclerosis; corneal ulceration; dental diseases such as gingivitis and periodontal disease; and neurological disorders such as multiple sclerosis. For example, in adenocarcinoma, invasive proximal gastric cells express the 72 kDa form of collagenase Type IV, whereas the noninvasive cells do not. Schwartz, G.K. et al., Cancer 73, 22-27 (1994). Rat embryo cells transformed by the Ha-ras and v-myc oncogenes or by Ha-ras alone are metastatic in nude mice and release the 92 kDa gelatinase/collagenase (MMP-9). Bernhard, E.J. et al., Proc. Natl. Acad. Sci. 91, 4293-4597 (1994). The plasma concentration of MMP-9 was significantly increased ($P < 0.01$) in 122 patients with gastrointestinal tract cancer and breast cancer. Zucker, S. et al., Cancer Res. 53, 140-146 (1993). Moreover, intraperitoneal administration of batimastat, a synthetic MMP inhibitor, gave significant inhibition in the growth and metastatic spread and number of lung colonies which were produced by intravenous injection of the B16-BL6 murine melanoma in C57BL/6N mice. Chirivi, R.G.S. et al., Int. J. Cancer 58, 460-464 (1994). Over-expression of TIMP-2, the endogenous tissue inhibitor of MMP-2, markedly reduced melanoma growth in the skin of immunodeficient mice. Montgomery, A.M.P. et al., Cancer Res. 54, 5467-5473 (1994).

Accelerated breakdown of the extracellular matrix of articular cartilage is a key feature in the pathology of both rheumatoid arthritis and osteoarthritis. Current evidence suggests that the inappropriate synthesis of MMPs is the key event. Beeley, N.R.A. et al., Curr. Opin. Ther. Patents, 4(1), 7-16 (1994). The advent of reliable diagnostic tools have allowed a number of research groups to recognize that stromelysin is a key enzyme in both arthritis and joint trauma. Beeley, N.R.A. et al., Id.; Hasty, K.A. et al., Arthr. Rheum. 33, 388-

397 (1990). It has also been shown that stromelysin is important for the conversion of procollagenase to active collagenase. Murphy, G. et al., Biochem. J. 248, 265-268 (1987).

Furthermore, a range of MMPs can hydrolyse the membrane-bound precursor of the pro-inflammatory cytokine tumor necrosis factor α (TNF- α). Gearing, A.J.H. et al., Nature 370, 555-557 (1994). This cleavage yields mature soluble TNF- α and the inhibitors of MMPs can block production of TNF- α both *in vitro* and *in vivo*. Gearing, A.J.H. et al., Id.; Mohler, K.M. et al., Nature 370, 218-220 (1994); McGeehan, G.M. et al., Nature 370, 558-561 (1994). This pharmacological action is a probable contributor to the antiarthritic action of this class of compounds seen in animal models. Beckett, R.P. et al., supra.

Stromelysin has been observed to degrade the α_1 -proteinase inhibitor which regulates the activity of enzymes such as elastase, excesses of which have been linked to chronic inflammatory disorders such as emphysema and chronic bronchitis. Inhibition of the appropriate MMP may thus potentiate the inhibitory activity of endogenous inhibitors of this type. Beeley, N.R.A. et al., supra; Wahl, R.C. et al., Annual Reports in Medicinal Chemistry 25, 177-184 (1990).

High levels of mRNA corresponding to stromelysin have been observed in atherosclerotic plaques removed from heart transplant patients. Henney, A.M., et al., Proc. Natl. Acad. Sci. 88, 8154-8158 (1991). It is submitted that the role of stromelysin in such plaques is to encourage rupture of the connective tissue matrix which encloses the plaque. This rupture is in turn thought to be a key event in the cascade which leads to clot formation of the type seen in coronary thrombosis. MMP inhibition is thus a preventive measure for such thromboses.

Collagenase, stromelysin and gelatinase have been implicated in the destruction of the extracellular matrix of the cornea. This is thought to be an important mechanism of morbidity and visual loss in a number of ulcerative ocular diseases, particularly those following infection or chemical damage. Burns, F.R. et al., Invest. Ophthalmol. and Visual Sci. 32, 1569-1575 (1989). The MMPs present in the eye during ulceration are derived either endogenously from infiltrating leucocytes or fibroblasts, or exogenously from microbes.

Collagenase and stromelysin activities have been identified in fibroblasts isolated from inflamed gingiva and the levels of enzyme have been correlated with the severity of the gingivitis observed. Beeley, N.R.A. et al., supra; Overall, C.M. et al., J. Periodontal Res. 22, 81-88 (1987).


Excessive levels of gelatinase-B in cerebrospinal fluid has been linked with incidence of multiple sclerosis and other neurological disorders. Beeley, N.R.A. et al., supra; Miyazaki, K. et al., Nature 362, 839-841 (1993). The enzyme may play a key role in the demyelination of neurones and the breakdown of the blood brain barrier which occurs in such disorders.

Existing MMP inhibitors already in development include pseudo-peptide derivatives developed by substrate-based design and other compounds identified from random screening of compound libraries and natural products. In the substrate-based design, a key to obtaining potent enzyme inhibition has been the incorporation of a zinc binding group (ZBG) to chelate the active site zinc(II) ion, into peptide analogs of the sequence on either the left-hand side (LHS) or the right-hand side (RHS), or both sides of the cleavage site. Several different ZBGs have been identified, namely, hydroxamate, carboxylate, aminocarboxylate, suphydryl and derivatives of phosphorous acids. While hydroxamate compounds, such as Batimastat, are currently undergoing clinical testing and have proven to be some of the most active compounds *in vitro*, they possess bioavailability problems and may also degrade into carcinogenic analogs, such as hydroxylamine.

It would thus be advantageous to provide additional matrix metalloproteinase inhibitors. It would also be advantageous to control the imbalance of matrix metalloproteinase without producing carcinogenic side-products.

SUMMARY OF THE INVENTION

The present invention provides novel compounds of the formula




5

wherein


- R_1 is C_1 - C_6 alkyl, a $W-(CH_2)_m$ group, or a $Q-Z-(CH_2)_m$ group wherein W is phthalimido; Z is a bond or is oxy, NR_6 , $C(O)NR_6$, $NR_6C(O)$, $NHC(O)NR_6$, $OC(O)NR_6$, $HNC(O)O$, or SO_2NR_6 ; Q is hydrogen, or a $Y-(CH_2)_n$ group wherein Y is hydrogen, C_6 - C_{10} aryl, C_3 - C_9 heteroaryl, $-C(O)OR_6$, $-N(R_6)_2$, morpholino, piperidino, pyrrolidino, or isoindolyl;
- R_2 is C_1 - C_4 alkyl, a $-(CH_2)_p$ -(C_3 - C_9)heteroaryl group, or a $-(CH_2)_p$ - Ar_1 group wherein Ar_1 is phenyl or naphthyl optionally substituted with a substituent selected from the group consisting of halogen, C_1 - C_4 alkyl, $-OR_7$, $-N(R_6)_2$, $SO_2N(R_6)_2$ or $-NO_2$;
- R_3 is hydrogen, C_1 - C_6 alkyl, $-CH_2SCH_2NHCOCH_3$, a $-(CH_2)_p$ -A group, a $-(CH_2)_m$ -B group or a $-CH_2-D-R_7$ group wherein A is C_6 - C_{10} aryl, C_3 - C_9 heteroaryl, or cyclohexyl; B is $-N(R_7)_2$, guanidino, nitroguanidino, $-C(O)OR_6$ or $-C(O)NR_6$; and D is oxy or thio;
- R_4 is hydrogen or a $-(CH_2)_m$ - $S(O)_pX'(R_6)_2$ group;
- R_5 is hydrogen, C_1 - C_6 alkyl or R_4 and R_5 taken together with the nitrogen atom to which they are attached form piperidino, pyrrolidino, or isoindolyl;
- R_6 is hydrogen or C_1 - C_6 alkyl;
- R_7 is hydrogen, C_1 - C_4 alkyl, or a $-(CH_2)_p$ - Ar_2 group wherein Ar_2 is phenyl or naphthyl optionally substituted with a substituent selected from the group consisting of halogen, C_1 - C_4 alkyl, $-OR_7$, $-N(R_6)_2$, $SO_2N(R_6)_2$ or $-NO_2$;
- R_8 is hydrogen, $-C(O)R_7$, a $-C(O)-(CH_2)_q$ -K group or a $-S-G$ group, wherein K is selected from the group consisting of

25

-6-



G is selected from the group consisting of



- 5 R_9 and R_{10} are each independently C_1 - C_4 alkyl or a $-(CH_2)_p-Ar_2$ group;
 R_{11} is $-CF_3$, C_1 - C_{10} alkyl or a $-(CH_2)_p-Ar_2$ group;




- R_{12} is hydrogen, C_1 - C_6 alkyl, $-CH_2CH_2S(O)_pCH_3$, or arylalkyl;
- R_{13} is hydrogen, hydroxy, amino, C_1 - C_6 alkyl, N-methylamino, N,N-dimethylamino, $-CO_2R_{17}$ or $-OC(O)R_{18}$ wherein R_{17} is hydrogen, $-CH_2O-C(O)C(CH_3)_3$, C_1 - C_4 alkyl, a $-(CH_2)_p-Ar_2$ group or diphenylmethyl and R_{18} is hydrogen, C_1 - C_6 alkyl or phenyl;
- 5 R_{14} is 1 or 2 substituents independently chosen from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, or halogen;
- R_{15} is hydrogen, C_1 - C_6 alkyl or a $-(CH_2)_p-Ar_2$ group;
- R_{16} is hydrogen or C_1 - C_4 alkyl;
- V_1 is O, S, or NH;
- 10 V_2 is N or CH;
- V_3 is a bond or $-C(O)-$;
- V_4 is $-(CH_2)_w-$, O, S, NR_7 , or $NC(O)R_{11}$;
- X and X' are each independently CH or N;
- m is an integer 2-4;
- 15 n is zero or an integer 1-4;
- p is zero or an integer 1-2;
- q is zero or an integer 1-5;
- t is an integer 1-2;
- w is an integer 1-3; and
- 20 w' is zero or an integer 1; or
- a pharmaceutically acceptable salt, stereoisomer or hydrate thereof.

The present invention further provides a method of inhibiting matrix metalloproteinases (MMPs) in a patient in need thereof comprising administering to the patient an
25 effective matrix metalloproteinase inhibiting amount of a compound of formula (1).

In addition, the present invention provides a composition comprising an assayable amount of a compound of formula (1) in admixture or otherwise in association with an inert carrier. The present invention also provides a pharmaceutical composition comprising an
30 effective MMP inhibitory amount of a compound of formula (1) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used in this application:

- 5 a) the designation "  " refers to a bond for which the stereochemistry is not designated.
- b) the designation "  " refers to a bond that protrudes forward out of the plane of the page.
- 10 c) the designation "  " refers to a bond that protrudes backward out of the plane of the page.

The expression "pharmaceutically acceptable salt" is intended to apply to any non-
15 toxic organic or inorganic salt of a compound of formula (1). Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono, di and tricarboxylic acids. Illustrative of such acids are, for example, acetic, trifluoroacetic,
20 glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid. Such salts can exist in either the hydrated or substantially anhydrous form.

25 As used herein, the term "C₁-C₄ alkyl" refers to a saturated straight or branched chain hydrocarbyl radical of one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl and the like. The term "C₁-C₆ alkyl" refers to a saturated straight or branched chain hydrocarbyl radical of one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, n-pentyl, sec-pentyl, isopentyl, n-
30 hexyl and the like. The term "C₁-C₁₀ alkyl" refers to a saturated straight or branched chain hydrocarbyl radical of one to ten carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, n-pentyl, sec-pentyl, isopentyl, n-hexyl, 2,3-dimethyl-2-butyl,

heptyl, 2,2-dimethyl-3-pentyl, 2-methyl-2-hexyl, octyl, 4-methyl-3-heptyl, nonyl, decyl and the like.

The term "C₁-C₄ alkoxy" refers to a straight or branched alkoxy group containing from 1 to 4 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, and the like.

The designation "-C(O)-" refers to a carbonyl group of the formula




The term "C₆-C₁₀ aryl" refers to a cyclic aromatic assemblage of conjugated carbon atoms, optionally substituted with one to three substituents selected from the group consisting of F, Cl, C₁-C₄ alkyl, -OR₇, -N(R₆)₂, or -NO₂, including phenyl, 1-naphthyl, 2-naphthyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 3,4-dihydroxyphenyl, 2,3,4-trihydroxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 4-bromophenyl, 3,4-dibromophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3-tolyl, 4-tolyl, 4-ethylphenyl, 4-isopropylphenyl, 3-aminophenyl, 4-aminophenyl, 3,4-diaminophenyl, N-methyl-4-aminophenyl, 2-nitrophenyl, 4-nitrophenyl, 3-bromo-4-tolyl, and the like.


The term "C₃-C₉ heteroaryl" means a cyclic or bicyclic, aromatic assemblage of conjugated carbon atoms and from 1 to 3 nitrogen, oxygen and sulfur atoms, for example, pyridinyl, 2-quinoxaliny, quinolinyl, pyridazine, pyrimidyl, pyrazolyl, pyrazyl, thiophyl, furyl, imidazolyl, oxazolyl, thiazolyl and the like.

The terms "PhtN" or "phthalimido" refer to a phthalimido functionality of the formula:

-10-




The terms "Boc", "t-butyloxycarbonyl", or "*tert*-butoxycarbonyl" refer to a t-butyloxycarbonyl functionality of the formula;




5

The terms "CBz" or "carbobenzyloxy" refer to a carbobenzyloxy functionality of the formula;



10

The designations "C(O)NR₆", "NR₆C(O)", "NHC(O)NR₆", "OC(O)NR₆", "R₆NC(O)O" or "SO₂NR₆" refer to amide bond or modified amide bond functionalities and are represented, respectively, by the following formulae:



15

The terms "Ar₁", "Ar₂" or "aryl" refers to a phenyl or naphthyl group unsubstituted or substituted with from one to three substituents selected from the group consisting of F, Cl, C₁-C₄ alkyl, -OR₇, -N(R₆)₂, SO₂N(R₆)₂ or -NO₂; specifically included within the scope of the

term "aralkyl" are phenyl, naphthyl, naphthylmethyl, phenylmethyl or benzyl, phenylethyl, p-methoxybenzyl, 3,4-methylenedioxybenzyl, p-fluorobenzyl and p-chlorobenzyl.

For the purposes of this invention, when "Ar₁" is phenyl, the substituent or substituents may only be attached at the 3, 4 or 5 positions of the phenyl moiety. When "Ar₁" is naphthyl, the radical can be attached at the 2-position, and the substituent or substituents may only be attached at the 5, 6, 7 or 8 positions, as illustrated by the following designations:



For the purposes of this invention, when "Ar₂" is phenyl, the substituent or substituents can be attached at the 2, 3, 4, 5 or 6 positions of the phenyl moiety. When "Ar₂" is naphthyl, it is understood that the radical can be attached at the either the 1-position or the 2-position, it is further understood that when the radical is attached at the 1-position the substituent or substituents can be attached in any of the 2, 3, 4, 5, 6, 7, or 8 positions and that when the radical is attached at the 2-position the substituent or substituents can be attached in any of the 1, 3, 4, 5, 6, 7, or 8 positions.

The term "halogen" refers to fluorine, chlorine, bromine or iodine.

The term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (*cis/trans*) isomers, and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers). Any reference in this application to one of the compounds of formula (1) is meant to encompass either specific stereoisomers or a mixture of stereoisomers. The specific stereoisomers can be prepared by stereospecific synthesis or can be separated and recovered by techniques known in the art, such as chromatography, chromatography on chiral stationary phases, fractional recrystallization of addition salts formed by reagents used for that purpose, as described in *Enantiomers, Racemates, and Resolutions*, J. Jacques, A. Collet, and S.H. Wilen, Wiley (1981).

One embodiment of the novel compounds is that of formula (I) wherein X is CH and R₈ is hydrogen.

5 In a class of this embodiment, R₁ is C₁-C₆ alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.


10 In another class of this embodiment, R₁ is a W-(CH₂)_m- group; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar₁ is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl
15 or isobutyl.

In another class of this embodiment, R₁ is a Q-Z-(CH₂)_m- group; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar₁ is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl,
20 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.

Exemplifying this embodiment are the following compounds of the Formulae II and III shown in Tables 1 and 2:

TABLE 1


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-1	PhtN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₃
II-2	PhtN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₂ CH ₃
II-3	PhtN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₂ CH ₂ CH ₃
II-4	PhtN-(CH ₂) ₄ -	phenyl	benzyl	-CH(CH ₃) ₂
II-5	PhtN-(CH ₂) ₄ -	phenyl	H	-CH ₃
II-6	PhtN-(CH ₂) ₄ -	phenyl	-CH ₃	-CH ₃
II-7	PhtN-(CH ₂) ₄ -	phenyl	-CH ₂ CH ₃	-CH ₃
II-8	PhtN-(CH ₂) ₄ -	phenyl	-CH ₂ CH ₂ CH ₃	-CH ₃
II-9	PhtN-(CH ₂) ₄ -	phenyl	-CH(CH ₃) ₂	-CH ₃
II-10	PhtN-(CH ₂) ₄ -	phenyl	-CH ₂ CH(CH ₃) ₂	-CH ₃
II-11	PhtN-(CH ₂) ₄ -	phenyl	-(CH ₂) ₃ CH ₃	-CH ₃
II-12	PhtN-(CH ₂) ₄ -	phenyl	-CH(CH ₃)CH ₂ CH ₃	-CH ₃
II-13	PhtN-(CH ₂) ₄ -	phenyl	phenyl	-CH ₃
II-14	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-15	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-16	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃

TABLE I (cont.)


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-17	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-18	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-19	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-20	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-21	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-22	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-23	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃

TABLE I (cont.)


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-24	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-25	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-26	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-27	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-28	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
II-29	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-30	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃

TABLE 1 (cont.)


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-31	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-32	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-33	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-34	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-35	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-36	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
II-37	PhtN-(CH ₂) ₄ -	-CH ₃	benzyl	-CH ₃
II-38	PhtN-(CH ₂) ₄ -	-(CH ₂) ₃ CH ₃	benzyl	-CH ₃

TABLE 1 (cont.)


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-39	PhN-(CH ₂) ₄ -		benzyl	-CH ₃
II-40			benzyl	-CH ₃
II-41			benzyl	-CH ₃
II-42	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃
II-43	-CH ₂ CH ₂ CH ₃			-CH ₃
II-44	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃
II-45	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₃
II-46	-CH ₂ CH ₂ CH ₃	benzyl	benzyl	-CH ₃
II-47	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₂ CH ₃
II-48	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₂ CH ₂ CH ₃

TABLE 1 (cont.)


Formula II



Compd. No.	R ₁	R ₂	R ₃	R ₅
II-49	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-(CH ₂) ₃ CH ₃
II-50	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-(CH ₂) ₄ CH ₃
II-51	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₃
II-52	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₂ CH ₃
II-53	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₂ CH ₂ CH ₃
II-54	-CH(CH ₃) ₂	phenyl	benzyl	-(CH ₂) ₃ CH ₃
II-55	-CH(CH ₃) ₂	phenyl	benzyl	-(CH ₂) ₄ CH ₃
II-56		phenyl	benzyl	-CH ₃
II-57		phenyl	benzyl	-CH ₂ CH ₃
II-58		phenyl	benzyl	-CH ₃
II-59		phenyl	benzyl	-CH ₃
II-60		phenyl	benzyl	-CH ₃

TABLE 2


Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-1	PhaN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₃
III-2	PhaN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₂ CH ₃
III-3	PhaN-(CH ₂) ₄ -	phenyl	benzyl	-CH ₂ CH ₂ CH ₃
III-4	PhaN-(CH ₂) ₄ -	phenyl	benzyl	-CH(CH ₃) ₂
III-5	PhaN-(CH ₂) ₄ -	phenyl	H	-CH ₃
III-6	PhaN-(CH ₂) ₄ -	phenyl	-CH ₃	-CH ₃
III-7	PhaN-(CH ₂) ₄ -	phenyl	-CH ₂ CH ₃	-CH ₃
III-8	PhaN-(CH ₂) ₄ -	phenyl	-CH ₂ CH ₂ CH ₃	-CH ₃
III-9	PhaN-(CH ₂) ₄ -	phenyl	-CH(CH ₃) ₂	-CH ₃
III-10	PhaN-(CH ₂) ₄ -	phenyl	-CH ₂ CH(CH ₃) ₂	-CH ₃
III-11	PhaN-(CH ₂) ₄ -	phenyl	-(CH ₂) ₃ CH ₃	-CH ₃
III-12	PhaN-(CH ₂) ₄ -	phenyl	-CH(CH ₃)CH ₂ CH ₃	-CH ₃
III-13	PhaN-(CH ₂) ₄ -	phenyl	phenyl	-CH ₃
III-14	PhaN-(CH ₂) ₄ -	phenyl		-CH ₃
III-15	PhaN-(CH ₂) ₄ -	phenyl		-CH ₃
III-16	PhaN-(CH ₂) ₄ -	phenyl		-CH ₃

TABLE 2 (cont.)


Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-17	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-18	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-19	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-20	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-21	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-22	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-23	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃

TABLE 2 (cont.)


Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-24	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-25	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-26	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-27	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-28	PhtN-(CH ₂) ₄ -	phenyl		-CH ₃
III-29	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-30	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃

TABLE 2 (cont.)


Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-31	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-32	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-33	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-34	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-35	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-36	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-37	PhtN-(CH ₂) ₄ -	-(CH ₂) ₃ CH ₃	benzyl	-CH ₃
III-38	PhtN-(CH ₂) ₄ -	-CH ₂ CH(CH ₃) ₂	benzyl	-CH ₃

TABLE 2 (cont.)


Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-39	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
III-40			benzyl	-CH ₃
III-41			benzyl	-CH ₃
III-42	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃
III-43	-CH ₂ CH ₂ CH ₃			-CH ₃
III-44	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃
III-45	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₃
III-46	-CH ₂ CH ₂ CH ₃	benzyl	benzyl	-CH ₃
III-47	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₂ CH ₃
III-48	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-CH ₂ CH ₂ CH ₃

TABLE 2 (cont.)

Formula III



Compd. No.	R ₁	R ₂	R ₃	R ₅
III-49	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-(CH ₂) ₃ CH ₃
III-50	-CH ₂ CH ₂ CH ₃	phenyl	benzyl	-(CH ₂) ₄ CH ₃
III-51	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₃
III-52	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₂ CH ₃
III-53	-CH(CH ₃) ₂	phenyl	benzyl	-CH ₂ CH ₂ CH ₃
III-54	-CH(CH ₃) ₂	phenyl	benzyl	-(CH ₂) ₃ CH ₃
III-55	-CH(CH ₃) ₂	phenyl	benzyl	-(CH ₂) ₄ CH ₃
III-56		phenyl	benzyl	-CH ₃
III-57		phenyl	benzyl	-CH ₂ CH ₃
III-58		phenyl	benzyl	-CH ₃
III-59		phenyl	benzyl	-CH ₃
III-60		phenyl	benzyl	-CH ₃

Another embodiment of the novel compounds is that of formula (1) wherein X is N and R₈ is hydrogen.

5 In a class of this embodiment, R₁ is C₁-C₆ alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar₁ is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.

10 In another class of this embodiment, R₁ is a W-(CH₂)_p- group; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar₁ is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.

15


In another class of this embodiment, R₁ is a Q-Z-(CH₂)_m- group; R₂ is C₁-C₄ alkyl, a -(CH₂)_p-Ar₁ group wherein Ar is phenyl optionally substituted with F, Cl, C₁-C₄ alkyl, or -OR₇ or is a -(CH₂)_p-(C₃-C₉)heteroaryl group wherein the (C₃-C₉)heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R₄ is hydrogen; R₅ is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.

20

Exemplifying this embodiment are the following compounds of the Formula IV shown in Table 3:

TABLE 3


Formula IV



Compd. No.	R ₁	R ₂	R ₃	R ₅
IV-1	PhtN-(CH ₂) ₄ -	benzyl	benzyl	-CH ₃
IV-2	PhtN-(CH ₂) ₄ -	benzyl	benzyl	-CH ₂ CH ₃
IV-3	PhtN-(CH ₂) ₄ -	benzyl	benzyl	-CH(CH ₃) ₂
IV-4	PhtN-(CH ₂) ₄ -	benzyl	H	-CH ₃
IV-5	PhtN-(CH ₂) ₄ -	benzyl	-CH ₃	-CH ₃
IV-6	PhtN-(CH ₂) ₄ -	benzyl	-CH(CH ₃) ₂	-CH ₃
IV-7	PhtN-(CH ₂) ₄ -	benzyl	-CH ₂ CH(CH ₃) ₂	-CH ₃
IV-8	PhtN-(CH ₂) ₄ -	benzyl	phenyl	-CH ₃
IV-9	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-10	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-11	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-12	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃

TABLE 3 (cont.)


Formula IV



Compd. No.	R ₁	R ₂	R ₃	R ₅
IV-13	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-14	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-15	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-16	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-17	PhtN-(CH ₂) ₄ -	benzyl		-CH ₃
IV-18	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃
IV-19	PhtN-(CH ₂) ₄ -		benzyl	-CH ₃

TABLE 3 (cont.)


Formula IV



Compd. No.	R ₁	R ₂	R ₃	R ₅
IV-20	PhN-(CH ₂) ₄ -		benzyl	-CH ₃
IV-21	PhN-(CH ₂) ₄ -		benzyl	-CH ₃
IV-22	PhN-(CH ₂) ₄ -	-(CH ₂) ₃ CH ₃	benzyl	-CH ₃
IV-23	PhN-(CH ₂) ₄ -	-CH ₂ CH(CH ₃) ₂	benzyl	-CH ₃
IV-24	PhN-(CH ₂) ₄ -		benzyl	-CH ₃
IV-25			benzyl	-CH ₃
IV-26			benzyl	-CH ₃
IV-27	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃

TABLE 3 (cont.)

Formula IV



Compd. No.	R ₁	R ₂	R ₃	R ₅
IV-28	-CH ₂ CH ₂ CH ₃	benzyl	benzyl	-CH ₃
IV-29	-CH ₂ CH ₂ CH ₃		benzyl	-CH ₃
IV-30	-CH ₂ CH ₂ CH ₃	benzyl	benzyl	-CH ₂ CH ₃
IV-31	-CH(CH ₃) ₂	benzyl	benzyl	-CH ₃
IV-32	-CH(CH ₃) ₂	benzyl	benzyl	-CH ₂ CH ₃
IV-33	-CH(CH ₃) ₂	benzyl	benzyl	-CH ₂ CH ₂ CH ₃
IV-34		benzyl	benzyl	-CH ₃
IV-35		benzyl	benzyl	-CH ₂ CH ₃
IV-36		benzyl	benzyl	-CH ₃
IV-37		benzyl	benzyl	-CH ₃
IV-38		benzyl	benzyl	-CH ₃


Another embodiment of the novel compounds is that of formula (1) wherein R_8 is R_8' and is defined as $-C(O)R_7$, a $-C(O)-(CH_2)_q-K$ group or a $-S-G$ group.

In a class of this embodiment, R_1 is C_1-C_6 alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl or isobutyl; R_2 is C_1-C_4 alkyl, a $-(CH_2)_p-Ar_1$ group wherein Ar_1 is phenyl optionally substituted with F, Cl, C_1-C_4 alkyl, or $-OR_7$ or is a $-(CH_2)_p-(C_3-C_9)$ heteroaryl group wherein the (C_3-C_9) heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R_4 is hydrogen; R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.


In another class of this embodiment, R_1 is a $W-(CH_2)_p$ group; R_2 is C_1-C_4 alkyl, a $-(CH_2)_p-Ar_1$ group wherein Ar_1 is phenyl optionally substituted with F, Cl, C_1-C_4 alkyl, or $-OR_7$ or is a $-(CH_2)_p-(C_3-C_9)$ heteroaryl group wherein the (C_3-C_9) heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R_4 is hydrogen; R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.

In another class of this embodiment, R_1 is a $Q-Z-(CH_2)_m$ group; R_2 is C_1-C_4 alkyl, a $-(CH_2)_p-Ar_1$ group wherein Ar_1 is phenyl optionally substituted with F, Cl, C_1-C_4 alkyl, or $-OR_7$ or is a $-(CH_2)_p-(C_3-C_9)$ heteroaryl group wherein the (C_3-C_9) heteroaryl group is thienyl, 2-pyridyl or thiazolyl; R_4 is hydrogen; R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl.


In another class of this embodiment, K is




In another class of this embodiment, G is




Exemplifying this embodiment are the following compounds disclosed below:




(V-1);




(V-2);




(V-3);






(V-4);






(V-5);




(V-6);







5 The compounds of formula (1) wherein X is CH can be prepared by utilizing techniques and procedures well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds is set forth in Scheme A wherein all substituents are as previously defined unless otherwise indicated.

SCHEME A


-36-

SCHEME A (cont.)





SCHEME A (cont.)


step j1




step k1




step j2



step k2



SCHEME A (cont.)

Scheme A provides a general synthetic procedure for preparing compounds of formula (1) wherein X is CH, that is, compounds of structures (17), (17a), (18) and (18a). The substituents R_1 , R_2 , R_3 , R_4 and R_5 are defined as above, while the substituent R_8' is defined as $-C(O)R_7$. The term "Me" stands for methyl, the term "PhtN" stands for phthalimido, "TMS" stands for trimethylsilyl and the term "TFA" signifies a trifluoroacetic acid salt.

In Scheme A, step a, the appropriate R_2 -substituted cyclohexanone of structure (2) is enolized with a non-nucleophilic base and quenched with a suitable electrophile, such as chlorotrimethylsilane, to form the corresponding R_2 -substituted enol ether, followed by treatment with ozone, dimethylsulfide, trimethylortho-formate and a suitable base to provide the appropriate R_2 -substituted acid of structure (3).

For example, lithium diisopropylamide (LDA) is generated by the addition of *n*-butyllithium to di-isopropylamine in the presence of a suitable organic solvent such as tetrahydrofuran (THF). A solution of R_2 -substituted cyclohexanone of structure (2) in a suitable organic solvent, such as THF, is then added at -78°C . After a period of time ranging from about 1 to 3 hours, the reaction is quenched with chloromethylsilane and the mixture is stirred followed by extraction and concentration of the organic layer to yield the silyl enol ether intermediate.

The silyl enol ether intermediate is then dissolved in a suitable organic solvent or solvent mixture, such as a methylene chloride/methanol mixture, cooled to -78°C and treated with ozone. Dimethyl sulfide is added and the reaction mixture is allowed to warm gradually to ambient temperature over a period of time ranging from 10 to 20 hours. The solution is then concentrated and treated with an orthoformate reagent such as trimethylorthoformate and an acid source such as acetyl chloride and heated to reflux. After a period of time ranging from 4 to 6 hours, the mixture is cooled to ambient temperature and treated with a suitable base, such as potassium hydroxide. The appropriate R_2 -substituted acid of structure (3) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation.

In Scheme A, step b, the appropriate R_2 -substituted acid of structure (3) is reacted with lithiated (S)-4-benzyl-2-oxazolidinone to provide the appropriate acyloxazolidinone of structure (4).

For example, the appropriate R_2 -substituted acid of structure (3) in a suitable organic solvent, such as tetrahydrofuran, is treated with a suitable tertiary organic amine such as triethylamine or N-methylmorpholine and cooled to -78°C . A suitable acid halide such as trimethylacetyl chloride is added and the mixture is transferred to an ice bath for 0.5 to 1.0 hours, then recooled to -78°C . The resulting slurry is treated with lithiated (S)-4-benzyl-2-oxazolidinone, prepared by adding n-butyllithium to (S)-4-benzyl-2-oxazolidinone in tetrahydrofuran, and allowed to warm gradually to ambient temperature over a period of time ranging from about 10 to 20 hours. The appropriate acyloxazolidinone of structure (4) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known and appreciated in the art, such as flash chromatography.

In Scheme A, step c, the appropriate acyloxazolidinone of structure (4) undergoes an azide alkylation reaction with a suitable azide transfer agent to provide the appropriate α -azidoacyloxazolidinone of structure (5).

For example, a solution of a suitable amide such as potassium bis(trimethylsilyl)amide in a suitable organic solvent, such as tetrahydrofuran, is cooled to -78°C and treated with a solution of the appropriate acyloxazolidinone of structure (4) in tetrahydrofuran, precooled to -78°C. A solution of a suitable azide transfer agent, such as triisopropylbenzenesulfonyl azide, in a suitable organic solvent, such as THF, precooled to -78°C is then added. The solution is stirred, quenched with acetic acid and transferred to an oil bath having a temperature of from about 25-40°C. After a period of time ranging from about 1 to 2 hours, the suspension is cooled to ambient temperature and water is added to obtain a solution. The appropriate α -azidoacyloxazolidinone of structure (5) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known in the art, such as flash chromatography.

In Scheme A, step d, the appropriate α -azidoacyloxazolidinone of structure (5) is converted to the corresponding α -azidoacid and then reacted with 2-trimethylsilylethanol to give the corresponding α -azidoester of structure (6).

For example, the appropriate α -azidoacyloxazolidinone of structure (5) in a suitable solvent such as tetrahydrofuran or tetrahydrofuran/water mixtures, is cooled and treated with hydrogen peroxide and a suitable base, such as lithium hydroxide. The mixture is stirred for about 1 to 2 hours and allowed to warm to ambient temperature and treated with Na₂SO₃. The corresponding α -azidoacid is isolated by methods well known and appreciated in the art, such as extraction and evaporation.

The corresponding α -azidoacid in a suitable organic solvent, such as tetrahydrofuran, is then treated sequentially at ambient temperature with 2-trimethylsilylethanol an organic amine, such as pyridine, and a condensing such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The mixture is then stirred for about 1 to 3 days and then concentrated. The corresponding α -azidoester of structure (6) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known and appreciated in the art, such as flash chromatography.

In Scheme A, step e, the α -azidoester of structure (6) is contacted with a suitable organic acid to provide the corresponding aldehyde-ester of structure (7).

For example, a solution of α -azidoester of structure (6) in the presence of an suitable
5 organic acid, such as acetic acid, and a suitable organic solvent, such as a tetrahydrofuran/water mixture, is heated at a temperature ranging from about 55°C to about 70°C for about 3 to 5 hours. The solution is then cooled and the corresponding aldehyde-ester of structure (7) is isolated by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known and
10 appreciated in the art, such as flash chromatography.

In Scheme A, step f, the aldehyde-ester of structure (7) is coupled with the R_3 -substituted amine salt of structure (7a) to provide the corresponding amino-ester of structure (8).

15 For example, a solution of the aldehyde ester of structure (7) and R_3 -substituted amine salt of structure (7a) in a hydroxylic solvent, such as methanol or ethanol, is treated with powdered activated 3A sieves. After about 30 minutes to 1 hour, the solution is reacted with a suitable reducing agent such as sodium cyanoborohydride, lithium cyanoborohydride, and the
20 like. The amino-ester of structure (8) is isolated by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known and appreciated in the art, such as flash chromatography.

In Scheme A, step g, the amino-ester of structure (8) is cyclized to give a mixture of
25 the cis α -azidolactam of structure (9) and the trans α -azidolactam of structure (10).

For example, a solution of the amino-ester of structure (8) in a suitable organic solvent, such as tetrahydrofuran, is treated at ambient temperature with a fluoride ion source, such as tetra-n-butylammonium fluoride, and stirred. After about 2 to 4 hours, the solution is
30 concentrated. The residue is then dissolved in a suitable organic solvent, such as ethyl acetate, washed with a suitable acid, such as 10% aqueous hydrochloric acid, and brine. The organic layer is then dried and concentrated to yield the corresponding crude amino acid.

The crude amino acid is then dissolved in a suitable organic solvent, such as tetrahydrofuran, cooled in an ice bath and treated sequentially with a suitable tertiary amine, such as N-methylmorpholine, and isobutyl chloroformate. The suspension is stirred for about
5 2 to 3 hours and filtered. The salts are washed with dry tetrahydrofuran and the filtrate is concentrated. The residue may be purified by methods well known and appreciated in the art, such as radial chromatography, to afford separately, the cis α -azidolactam of structure (9) and the trans α -azidolactam of structure (10).

10 In Scheme A, steps h1 and h2, the cis α -azidolactam of structure (9) and the trans α -azidolactam of structure (10), respectively, are converted to the corresponding cis α -aminolactam of structure (11) and the trans α -aminolactam of structure (12), respectively.

For example, a solution of cis α -azidolactam of structure (9) or trans α -azidolactam of
15 structure (10) in a protic solvent, such as methanol or ethanol, is degassed and treated with an alkyl dithiol, such as 1,3-propanedithiol and a tertiary amine, such as triethylamine. The solution is stirred from 60 to 72 hours and then concentrated. The residue may be purified by methods well known and appreciated in the art, such as flash chromatography, to afford the corresponding cis α -aminolactam of structure (11) or the trans α -aminolactam of structure
20 (12), respectively.

In Scheme A, steps i1 and i2, the cis α -aminolactam of structure (11) and the trans α -aminolactam of structure (12), respectively, are coupled with the bromoacid of structure (12a) to provide the bromoamides of structures (13) and (14), respectively.

25

For example, a mixture of cis α -aminolactam of structure (11) or trans α -aminolactam of structure (12), a bromoacid of structure (12a), a carbodiimide, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and 1-hydroxybenzotriazole (HOBt) in a suitable organic solvent such as methylene chloride was stirred at ambient
30 temperature for 15 to 25 hours. The cis bromoamide of structure (13) or the trans bromoamide of structure (14) may be isolated by methods well known and appreciated in the art, such as

extraction and evaporation. The product can be purified by methods well known and appreciated in the art, such as flash chromatography.

In Scheme A, steps j1 and j2, the cis bromoamide of structure (13) and the trans
5 bromoamide of structure (14), respectively, are converted to the cis α -thioamide of structure (15) and the trans α -thioamide of structure (16), respectively.

For example, a solution of p-methoxybenzylmercaptan in a suitable organic solvent
such as dimethylformamide is degassed and treated with a suitable base such as sodium
10 hydride. After about 1 to 2 hours, a solution of bromoamide of structure (13) or structure (14)
in a suitable organic solvent, such as dimethylformamide is added to the mercaptide formed
immediately above, as well as a suitable phase transfer catalyst, such as tetra-n-
butylammonium iodide. The reaction mixture is stirred for 15 to 25 hours and saturated
aqueous ammonium chloride solution and water are added. The cis α -thioamide of structure
15 (15) or the trans α -thioamide of structure (16), respectively, may be isolated by methods well
known and appreciated in the art, such as extraction and evaporation. The product can be
purified by methods well known and appreciated in the art, such as flash chromatography.


In Scheme A, steps k1 and k2, cis α -thioamide of structure (15) and the trans α -
20 thioamide of structure (16), respectively, are cleaved to provide the compounds of structures
(17) and (18), respectively, which represent the compounds of formula (1) where X is CH.

For example, a mixture of cis α -thioamide of structure (15) or the trans α -thioamide of
structure (16), mercuric acetate and anisole in a suitable organic solvent, such as methylene
25 chloride is cooled in an ice bath, degassed, and treated with a suitable acid, such as
trifluoroacetic acid. After a time period of about 3-6 hours, hydrogen sulfide gas is bubbled in
the reaction mixture for about 10 to 20 minutes. The compounds of structures (17) and (18),
which represent the compounds of formula (1) where X is CH, may be isolated by methods
well known and appreciated in the art, such as extraction and evaporation. The product can be
30 purified by methods well known and appreciated in the art, such as flash chromatography.

In Scheme A, optional steps 11 and 12, the thiol functionality of compounds (17) and (18) are acylated with an R_8' -acylating agent, wherein R_8' is defined as above, to provide the compounds (17a) and (18a).

5 For example, the appropriate compound of structures (17) or (18) can be contacted with a molar equivalent of an appropriate R_8' -acylating agent such as acetic anhydride and a catalytic amount of an acid such as sulfuric acid. The reactants are typically stirred together for a period of time ranging from 10 minutes to 10 hours. The compounds of structures (17a) and (18a) may be isolated by methods well known and appreciated in the art, such as
10 extraction and evaporation. The products can be purified by methods well known and appreciated in the art, such as flash chromatography.

 The R_2 -substituted cyclohexanones of structure (2) can be prepared by utilizing techniques and procedures well known and appreciated by one of ordinary skill in the art. A
15 general synthetic scheme for preparing these compounds is set forth in Scheme A1 wherein all substituents are as previously defined unless otherwise indicated.

SCHEME A1

5 Scheme A1 provides a general synthetic procedure for preparing compounds of formula (2) wherein the substituents are defined as above, unless otherwise indicated.

10 In Scheme A1, step a, the ketone of structure (2d) is reacted with an organolithium compound of the formula R_2Li or a Grignard reagent of the formula $R_2Mg-Hal$, where "Hal" is halogen, according to techniques well known in the art to provide the tertiary alcohol of structure (2c).

For example, an appropriate Grignard reagent of structure R_2MgBr in a suitable organic solvent, such as ethyl ether is added to a solution of the ketone of structure (2d) in a suitable organic solvent, such as anhydrous ethyl ether. The reaction mixture is stirred and then cooled to about $0^\circ C$. Saturated ammonium chloride solution is then added. The ethereal
5 layer is separated, washed with water and dried ($MgSO_4$). The solvent is evaporated *in vacuo* and purified by silica gel chromatography to give the tertiary alcohol of structure (2c).

An appropriate Grignard reagent of structure $R_2Mg-Hal$ can be prepared by techniques well known in the art. For example, magnesium turnings and anhydrous ethyl ether are mixed
10 under an inert atmosphere. A solution of a compound of the formula R_2-Hal , where Hal is halogen, in ethyl ether is then added to the magnesium mixture. The mixture is then stirred until the magnesium metal dissolves to give the Grignard reagent of structure $R_2Mg-Hal$.

In Scheme A1, step b, the tertiary alcohol of structure (2c) is dehydrated according to
15 techniques well known in the art to give the intermediate of structure (2b).

For example, the tertiary alcohol of structure (2c) may be dehydrated according to the procedure disclosed by Yadav, J.S. and Mysorekar, S.V., Synth. Comm. 19, 1057-1060 (1989). For example, to a stirred solution of the tertiary alcohol of structure (2c) in methylene
20 chloride is added triethylamine and DMAP. The mixture is then cooled to about $0^\circ C$ and methanesulfonyl chloride is added dropwise to the mixture. The resulting reaction mixture is stirred for about 1 hour at room temperature. Crushed ice is added and the mixture stirred for about 1 hour. Afterwards, the reaction mixture is extracted with methylene chloride. The organic extracts are combined, washed with water and dried (Na_2SO_4). The solvent is then
25 evaporated and the products are purified by methods well known and appreciated in the art, such as silica gel chromatography to provide the intermediate of structure (2b).

In Scheme A1, step c, the intermediate of structure (2b) is reduced to provide the ketal of structure (2a).


30


For example, a solution of the intermediate of structure (2b) in a suitable organic solvent, such as methanol, may be treated with 10% palladium/carbon catalyst (Pd-C) and stirred under a hydrogen atmosphere for a period of from 10-20 hours. Additional catalyst


may then be added, the mixture may be stirred for an additional 5-10 hours, degassed and filtered. The filtrate is then concentrated to yield the ketal of structure (2a).

In Scheme A1, step d, the ketal of structure (2a) is hydrolyzed according to procedures
5 well known in the art to provide the R₂-substituted cyclohexanone of structure (2). For
example, the blocked ketone functionality of the compound of structure (2a) may be
hydrolyzed according to the procedure disclosed by Honan, M.C., Tetrahedron Lett. 26, 6393-
6396 (1985) or Greico, P.A. et al., J. Amer. Chem. Soc. 99, 5773-5780 (1977). For example,
10 the ketal of structure (2a) is dissolved in a solution of a tetrahydrofuran/5% hydrochloric acid
mixture (2:1) and allowed to react for a period of time ranging from about 15 to 25 hours at
room temperature. The solvent is then removed under reduced pressure to afford the R₂-
substituted cyclohexanone of structure (2).

The compounds of formula (1) wherein X is N can be prepared by utilizing techniques
15 and procedures well known and appreciated by one of ordinary skill in the art. A general
synthetic scheme for preparing these compounds is set forth in Scheme B wherein all
substituents are as previously defined unless otherwise indicated.

SCHEME B

SCHEME B (cont.)

SCHEME B (cont.)

5 Scheme B provides a general synthetic procedure for preparing compounds of formula (1) wherein X is N, that is, compounds of structures (32) and (32a). The substituents R_1 , R_2 , R_3 , R_4 , R_5 , R_8' , Me, Phth, Boc and TFA are defined as above. The term "TMS" represents trimethylsilyl.

10 In Scheme B, step a, *N-tert*-butoxycarbonyl-L-serine (19) is converted to *N-tert*-butoxycarbonyl-L-serine β -lactone (20).

For example, *N-tert*-butoxycarbonyl-L-serine (19) is converted to *N-tert*-butoxycarbonyl-L-serine β -lactone (20) using techniques and procedures well known in the art. For example, *N-tert*-butoxycarbonyl-L-serine (19) may be reacted with diethyl azodicarboxylate (DEAD) and triphenylphosphine (Ph_3P) under Mitsunobu conditions or as described in Pansare, S.V. et al., Org. Synth. 70, 10 (1991) to provide *N-tert*-butoxycarbonyl-L-serine β -lactone (20). The product may be isolated by well known techniques such as

extraction and evaporation and may be purified by well known methods such as chromatography.

In Scheme B, step b, *N*-*tert*-butoxycarbonyl-L-serine β -lactone (20) is reacted with allyl amine to provide the amino acid of structure (21).

For example, a solution of *N*-*tert*-butoxycarbonyl-L-serine β -lactone (20) in a suitable organic solvent, such as acetonitrile (CH_3CN) is added to a solution of allyl amine in a suitable organic solvent, such as acetonitrile. The amino acid of structure (21) may be isolated using well known techniques such as evaporation. A hydroxamide byproduct may be recovered by concentration of the filtrate.

In Scheme B, step c, the amino acid of structure (21) is Z-protected at the secondary amine and the Boc-protecting group at the primary amine is replaced with a phthalimido group to provide the desired phthalimido acid of structure (22).

For example, a solution of amino acid of structure (21) in saturated aqueous NaHCO_3 and water is reacted with a solution of benzyl chloroformate in a suitable organic solvent, such as acetone. The reactants are typically stirred together at ambient temperature for a period of time ranging from about 2-10 hours. The CBz-amino acid intermediate can be recovered from the reaction zone by extractive techniques known in the art. It may be used without further purification.

A solution of the CBz-amino acid intermediate in a suitable organic solvent such as methylene chloride is then treated with trifluoroacetic acid. The reactants are typically stirred at ambient temperature for 1-4 hours and concentrated. The trifluoroacetic acid salt intermediate is recovered from the reaction zone by extractive techniques and may be used without further purification.

A solution of the trifluoroacetic acid salt intermediate in a water:ethereal solvent mixture, such as water:dioxane, and solid Na_2CO_3 is treated with *N*-carbethoxyphthalimide (NCEP). The reactants are typically stirred for 3-10 hours at a temperature ranging from about 30°C to about 50°C. After stirring, additional Na_2CO_3 is added to bring the pH of the reaction

mixture to approximately pH 8-10. N-carbethoxyphthalimide (NCEP) is re-added and the reaction is stirred an additional 12 to 24 hours. The phthalimido acid of structure (22) may be recovered from the reaction zone by extractive methods as are known in the art. It may be purified by known purification techniques such as flash chromatography.

5

In Scheme B, step d, the acid functionality of the phthalimido acid of structure (22) is converted to a trimethylsilyl ester functionality to provide the ester of structure (23).

For example, a solution of the phthalimido acid of structure (22) in a suitable organic solvent or solvent mixture, such as tetrahydrofuran and methylene chloride is treated with 2-trimethylsilylethanol; a suitable organic amine, such as pyridine, triethylamine, N-methylmorpholine, and the like; and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The reactants are typically stirred for 12-24 hours at ambient temperature. The desired ester of structure (23) may be isolated from the reaction zone by extraction and evaporation and may be purified by flash chromatography.

15

In Scheme B, step e, the ester of structure (23) is oxidized to afford the aldehyde of structure (24).

For example, a solution of the ester of structure (23) in a suitable organic solvent or solvent mixture, such as methylene chloride and methanol, is cooled to approximately -78°C, under an inert atmosphere, such as argon. Ozone is then passed through the solution for a sufficient time, typically until a blue color persists. Excess ozone may be purged from the solution by bubbling argon through the solution for a period of time ranging from 10-20 minutes. A suitable reducing agent such as dimethyl sulfide may then be added and the solution is allowed to warm gradually to ambient temperature for a period of from about 6-20 hours. The aldehyde of structure (24) may be obtained from the reaction zone by extraction and evaporation and may be purified by flash chromatography.

25

In Scheme B, step f, the aldehyde of structure (24) is coupled with the R₃-substituted amine salt of structure (7a) to provide the corresponding amino-ester of structure (25).

30

For example, a solution of the aldehyde of structure (24) and R_3 -substituted amine salt of structure (7a) in a protic solvent, such as methanol or ethanol, is typically stirred for 10-20 minutes, treated with sodium cyanoborohydride, and then stirred for approximately 3-6 hours. The amino-ester of structure (25) is recovered from the reaction zone by extraction and
5 evaporation and is purified by flash chromatography.

In Scheme B, step g, the amino-ester of structure (25) is cyclized in a manner analogous to the procedures described in Scheme A, step g, to give the CBz-lactam of structure (26).
10

In Scheme B, step h, the CBz-protected amine functionality of the Z-lactam of structure (26) is deprotected to afford the lactam of structure (27).

For example, a solution of the Z-lactam in a suitable organic solvent, such as methanol,
15 may be treated with 10% palladium/carbon catalyst (Pd-C) and stirred under a hydrogen atmosphere for a period of from 10-20 hours. Additional catalyst may then be added, the mixture may be stirred for an additional 5-10 hours, degassed and filtered. The filtrate is then concentrated to yield the lactam of structure (27).

In Scheme B, step i, the lactam of structure (27) is reacted with an R_2 -substituted halide of the formula R_2 -Hal, wherein "Hal" is Cl, Br or I, to provide the R_2 -substituted lactam of structure (28).
20

For example, a solution of the lactam of structure (27), in a suitable organic solvent or solvent mixture, such as acetonitrile and dimethylformamide, is treated with an appropriate R_2 -substituted halide and solid K_2CO_3 . After a period of time ranging from about 12-24 hours, the desired lactam of structure (28) is isolated from the reaction zone by extraction and evaporation and is purified by flash chromatography.
25

In Scheme B, step j, the phthalimido-protected amine functionality of the lactam of structure (28) is deprotected to provide the amine of structure (29).
30

For example, a solution of the lactam of structure (28) in a suitable organic solvent such as methanol, is contacted with two molar equivalents of hydrazine hydrate in a suitable organic solvent such as methanol. The reaction is typically carried out at ambient temperature. The reaction mixture is then stirred for a period of time ranging from about 60-90 hours and is
5 then filtered. The filtrate is concentrated to afford the amine of structure (29).

In Scheme B, step k, the amine of structure (29) is coupled with the bromoacid of structure (12a) in a manner analogous to the procedures described in Scheme A, steps i1 and i2, to give the bromoamide of structure (30).
10

In Scheme B, step l, the bromoamide of structure (30) is converted to the α -thioamide of structure (31).

For example, a solution of bromoamide (30) and p-methoxybenzylmercaptan in a
15 suitable organic solvent, such as dimethylformamide, is degassed and treated at ambient temperature with cesium carbonate. After a period of time ranging from 12-24 hours, the α -thioamide of structure (31) is isolated from the reaction zone by extraction and evaporation and is purified by flash chromatography.

Alternatively, the bromoamide of structure (30) may be converted to the α -thioamide of structure (31) in a manner analogous to the procedures of Scheme A, steps j1 and j2.
20

In Scheme B, step m, the α -thioamide of structure (31) is cleaved in a manner analogous to the procedures of Scheme A, steps k1 and k2 to provide the compound of
25 structure (32), which corresponds to a compound of formula (I) wherein X is N and R₈ is H.


In Scheme B, optional step n, the thiol functionality of the compound structure (32) is acylated in a manner analogous to the procedures of Scheme A, steps l1 and l2 to provide a compound of structure (32).
30

Starting materials for use in Schemes A and B are readily available to one of ordinary skill in the art. For example, certain R₂-substituted cyclohexanones of structure (2) are commercially available, such as 4-phenylcyclohexanone, 4-methylcyclohexanone, 4-

ethylcyclohexanone, 4-t-butylcyclohexanone are available from Aldrich Chemical Co., Inc., Milwaukee, Wisconsin 53233.

The R_3 -substituted amine salt of structure (7a) can be prepared by utilizing techniques and procedures well known and appreciated by one of ordinary skill in the art. A general synthetic scheme is set forth in Scheme C wherein all the substituents are as previously defined unless otherwise indicated.

SCHEME C



In step a, the protected amino acid of structure (7c) is amidated to provide the amino amide of structure (7b).

15

For example, a solution of the protected amino acid of structure (7c) in a suitable organic solvent such as tetrahydrofuran is cooled from about -25°C to about -40°C and treated sequentially with a slight molar excess of tertiary amine, such as N-methylmorpholine, and a slight molar excess of isobutylchloroformate. After a period of time ranging from about 10 to 20 minutes, the reaction mixture is treated with a molar excess of an amine of the formula $\text{H}_2\text{NR}_4\text{R}_5$, wherein R_4 and R_5 are as defined above, stirred for about 1-4 hours and concentrated. The residue is dissolved in a suitable organic solvent, such as methylene chloride, washed with an appropriate acid, such as hydrochloric acid and sodium carbonate

(NaHCO₃). The organic layer is dried with a suitable drying agent, such as sodium sulfate and concentrated to provide crude amino amide of structure (7b).

In Scheme C, step b, the amino amide of structure (7b) is deprotected to provide the
5 R₃-substituted amine salt of structure (7a).


For example, a solution of crude amino amide of structure (7b) in a suitable organic solvent, such as methylene chloride and trifluoroacetic acid is stirred at ambient temperature from about 2 to about 4 hours and concentrated. Residual trifluoroacetic acid may be removed
10 by coevaporation with a suitable solvent mixture, such as carbon tetrachloride and toluene using a rotary evaporator. The R₃-substituted amine salt of structure (7a) is then isolated and purified by techniques well known and appreciated by one of ordinary skill in the art.

Starting materials for use in Scheme C are readily available to one of ordinary skill in
15 the art. For example, N-protected amino acids of structure (7c) are commercially available or are easily made by one of ordinary skill in the art. Furthermore, amines of the formula H₂NR₄R₅, wherein R₄ and R₅ are defined as above, are commercially available or are easily made by one of ordinary skill in the art. Examples of amines of formula H₂NR₄R₅, which are
20 commercially available from Aldrich Chemical Co., Inc. include methylamine, ethylamine, propylamine, isopropylamine, butylamine, R-(-)-*sec*-butylamine, (±)-*sec*-butylamine, S-(+)-*sec*-butylamine, *tert*-butylamine, hexylamine, morpholine, piperidine and pyrrolidine.

The bromoacids of structure (12a) are commercially available or can be prepared utilizing materials, techniques and procedures well known and appreciated by one of ordinary
25 skill in the art. Examples of bromoacids of structure (12a) which are commercially available include 2-bromopropionic acid, 2-bromobutyric acid, 2-bromovaleric acid, 2-bromohexanoic acid, 6-(benzoylamino)-2-bromohexanoic acid, α-bromoheptanoic acid, 2-bromooctanoic acid, 2-bromo-3-methylbutyric acid, α-bromoisocaproic acid, α-bromo-β-(5-imidazolyl)proionic acid, (R)-(+)-2-bromopropionic acid, (S)-(-)-2-bromopropionic acid.

30

The bromoacids of structure (12a) wherein R₁ is a W-(CH₂)_m- group are synthesized according to Scheme D. The bromoacid of structure (35) corresponds to the bromoacid of structure (12a) when R₁ is a W-(CH₂)_m- group.

SCHEME D

5

In Scheme D, step a, the amino carboxylic acid of structure (33) in a suitable polar solvent, such as water or a water:etheral solvent mixture, is treated with Na_2CO_3 and N-carbethoxy phthalimide (NCEP). The reaction mixture is typically stirred at ambient temperature for 1-5 hours and extracted by extractive methods well known in the art. The aqueous layer is then cooled and acidified to about pH 1 using an acid, such as concentrated hydrochloric acid. The precipitate is then collected by filtration, washed with water and then dried to give the phthalimido carboxylic acid of structure (34).

10

In Scheme D, step b, the phthalimido carboxylic acid of structure (34) is brominated to give the 2-bromo-phthalimido carboxylic acid of structure (35). For example, a mixture of the phthalimido carboxylic acid of structure (34) and dry red phosphorous is treated dropwise with
5 bromine at temperature ranging from about -20° to about 10°C. The reaction mixture is then warmed to room temperature and then heated to about 80°C for about 2-5 hours. The reaction mixture is then cooled to room temperature, poured into water containing NaHSO₃, and neutralized using solid NaHCO₃. The aqueous layer is washed with an ethereal solvent, such as diethyl ether, and acidified with a suitable acid, such as concentrated hydrochloric acid.
10 The precipitate is collected by filtration and dried to yield the bromoacid of structure (35).

Alternatively, the bromoacid of structure (35) can be prepared following the procedure described in Scheme D, steps a1, a2 and b1, as described analogously by Baldwin, J.E. et al., Tetrahedron 44, 2633-2636 (1988) and Bezas, B. and Zervas, L., J. Am. Chem. Soc. 83, 719-
15 722 (1961).

For example, in Scheme D, step a1, selective N- α -protection of a suitable α -amino acid, such as L-lysine, is accomplished by masking the ϵ -amino group by formation of a benzylidene imine. The benzylidene imine is formed by dissolving L-lysine
20 monohydrochloride in lithium hydroxide and cooling the solution to a temperature ranging from about 0° to 10°C. Freshly distilled benzaldehyde is then added and the solution is shaken. N- ϵ -benzylidene-L-lysine is recovered by filtration and evaporation.

The α -amino group of the N- ϵ -benzylidene-L-lysine then undergoes urethane
25 protection, followed by hydrolytic cleavage of the imine *in situ* to give N- α -benzyloxycarbonyl-L-lysine. For example, N- ϵ -benzylidene-L-lysine is added to a mixture of sodium hydroxide and ethanol, cooled to a temperature of from about -5° to about -25°C. Then, precooled solutions of benzyloxycarbonyl chloride in an alkaline solvent, such as sodium hydroxide and ethanol, are added to the reaction mixture. The temperature is maintained at a
30 temperature ranging from about -10° to about -25°C during the course of addition, and then allowed to rise slightly (approx. -5°C) with stirring. The reaction mixture is then acidified using a suitable acid, such as precooled hydrochloric acid, and N- α -benzyloxycarbonyl-L-

lysine, which corresponds to structure (34a) where m is 4, is recovered by filtration and recrystallization.

In Scheme D, step a2, N- α -benzyloxycarbonyl-L-lysine or other compounds of structure (34a) are reacted with N-carboethoxyphthalimide in aqueous sodium carbonate solution to yield optically pure phthaloyl derivatives of the compounds of structure (34a).

The phthaloyl derivatives of the compounds of structure (34a) are then reduced concurrently with carbobenzoxy hydrogenolysis to give the N- ϵ -phthaloyl amino acids of structure (34b). For example, the individual phthaloyl derivative of structure (34a) is contacted with a catalytic amount of a hydrogenation catalyst, such as 10% palladium/carbon. The reactants are typically contacted in a suitable solvent mixture such as tetrahydrofuran/water. The reactants are typically shaken under a hydrogen atmosphere of 35-45 psi at room temperature for a period of time ranging from 5-24 hours. The individual N- ϵ -phthaloyl amino acid of structure (34b) is recovered from the reaction zone by evaporation of the solvent.


In Scheme D, step b1, the individual N- ϵ -phthaloyl amino acid of structure (34b) is deaminobrominated to yield the bromoacid of structure (35). This reaction can be performed utilizing a reaction of the type described in Compagnone, R.S. and Rapoport, H., J. Org. Chem., 51, 1713-1719 (1986); U.S. Pat. No. 5,322,942, issued June 21, 1994; Overberger, C.G. and Cho, I., J. Org. Chem., 33, 3321-3322 (1968); or Pfister, K. et al., J. Am. Chem. Soc., 71, 1096-1100 (1949).

For example, a mixture of N- ϵ -phthaloyl amino acid of structure (34b) and a suitable bromide, such as hydrogen bromide or potassium bromide, in acidic solution, such as sulfuric acid, is treated with sodium nitrite. If avoidance of racemization caused by excess bromide ion is desired, the reaction temperature can be kept between -5°C and 0°C during addition and stirring. After the reaction mixture is stirred for a period of time ranging from 1.5 to 5 hours, the bromoacid of structure (35) may be recovered by extraction and evaporation.

The bromoacids of structure (12a) wherein R_1 is C_1 - C_6 alkyl or a Q' - Z' -(CH_2) $_m$ - group, wherein m is as defined above and Q' is hydrogen or a Y' -(CH_2) $_n$ - group, wherein Y' is - $C(O)OR_6$; Z' is a bond, oxy or amino, are synthesized according to Scheme E. The bromoacid of structure (37) corresponds to the bromoacid of structure (12a) when R_1 is C_1 - C_6 alkyl, or a

5 Q' - Z' -(CH_2) $_m$ - group.

SCHEME E



10

Scheme E provides a general synthetic procedure for preparing the bromoacids of structure (12a) when R_1 is C_1 - C_6 alkyl or a Q' - Z' -(CH_2) $_m$ - group, signified as structure (37).

15 The substituent R_1' is defined as C_1 - C_6 alkyl, or a Q' - Z' -(CH_2) $_m$ - group.

20


In Scheme E, an appropriate amino acid of structure (36) is deaminobrominated to yield the R_1' -substituted bromoacid of structure (37) as described previously in Scheme D, step b1.

The amino acids of structure (36), and N-protected forms thereof, are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, L-alanine, D-alanine, L-valine, D-valine, D-norvaline, L-leucine, D-leucine, D-isoleucine, D-tert-leucine, glycine, L-glutamic acid, D-glutamic acid, L-glutamine, D-glutamine, L-lysine, D-lysine, L-ornithine, D-ornithine,



25 (D)-(-)-2-aminobutyric acid, D-threonine, D-homoserine, D-allothreonine, D-serine, D-2-aminoadipic acid, D-aspartic acid, D-glutamic acid, D-lysine hydrate, 2,3-diaminopropionic acid monohydrobromide, D-ornithine hydrochloride, D,L-2,4-diaminobutyric acid dihydrochloride, L-meta-tyrosine, D-4-hydroxyphenylglycine, D-tyrosine, D-phenylalanine,


D,L-2-fluorophenylalanine, beta-methyl-D,L-phenylalanine hydrochloride, D,L-3-fluorophenylalanine, 4-bromo-D,L-phenylalanine, D-2-phenylglycine, D,L-4-fluorophenylalanine, 4-iodo-D-phenylalanine, D-homophenylalanine, D,L-2-fluorophenylglycine, D,L-4-chlorophenylalanine, and the like, are all commercially available
5 from Sigma Chemical Co., St. Louis, Mo. or Aldrich Chemical Co., Inc.

The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^2-Z'^2-(CH_2)_m$ - group wherein Q'^2 is a $Y'^2-(CH_2)_n$ - group, where Y'^2 is $-N(R_6)_2$, can be synthesized according to techniques well known
10 and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds is set forth in Scheme F wherein all substituents, unless otherwise indicated, are previously defined. The α -thioamide of structure (38) generically represents the cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) when R_1 is a $Q'^2-Z'^2-(CH_2)_m$ - group wherein Q'^2 is a $Y'^2-(CH_2)_n$ - group, where
15 Y'^2 is $-N(R_6)_2$.

SCHEME F

step a

optional
step boptional
step c

SCHEME F (cont.)

5

Scheme F provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $Q'^2-Z'^2-(CH_2)_m-$ group wherein Q'^2 is a $Y'^2-(CH_2)_n-$ group, where Y'^2 is $-N(R_6)_2$. All of the substituents are as defined above except R_6' which is defined as C_1-C_6 alkyl.

10

In Scheme F, step a, the phthalimido group of the appropriate individual α -thioamide compounds of structure (38) is contacted with a molar excess of hydrazine monohydrate. The reactants are typically contacted in a protic organic solvent, such as methanol. The reactants are typically stirred together at room temperature for a period of time ranging from 5-24 hours.

15 The corresponding free amine compounds of structure (39) are recovered from the reaction zone by evaporation of the solvent, redissolving in $CHCl_3$, filtration to remove phthalhydrazide and removal of the $CHCl_3$ in vacuo.


20 In Scheme F, optional step b, the individual free amines of structure (39) are converted to the R_6' -substituted amines of structure (40) by reductive alkylation.

For example, the a mixture of the free amine of structure (39) in a protic organic solvent, such as methanol, is contacted with $R_6'CHO$, sodium cyanoborohydride and 1 drop of 1% bromocresol green in methanol. The pH of the reaction is maintained with 1N

hydrochloric acid in methanol. The R_6' -substituted amines of structure (40) are recovered from the reaction zone by extraction and evaporation of the solvent.

5 In Scheme F, optional step c, the R_6' -substituted amines of structure (40) is converted to the di- R_6' -substituted amines of structure (41) as described above in Scheme E, optional step b.

10 The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^3-Z'^3-(CH_2)_m$ - group, wherein Q'^3 is a $Y'^3-(CH_2)_n$ - group, Z'^3 is $CONR_6$, and Y'^3 is H, C_6 - C_{10} aryl, C_3 - C_9 heteroaryl, morpholino, piperidino, pyrrolidino or isoindolyl can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (43), is set forth in Scheme G wherein all substituents, unless otherwise indicated, are previously defined.

SCHEME G

5 Scheme G provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $Q'^3-Z^3-(CH_2)_m-$ group wherein Q'^3 is a $Y'^3-(CH_2)_n-$ group, Z^3 is $CONR_6$, and Y'^3 is H, C_6-C_{10} aryl, C_3-C_9 heteroaryl, morpholino, piperidino, pyrrolidino or isoindolyl. All of the other substituents are as previously defined.

10 In Scheme G, the compounds of structure (43) are prepared by coupling the free amine of structure (39) or the R_6' -substituted amines of structure (40) with the acid of structure (42). Specifically, an acid of structure (42) is contacted with 1.2 to 1.7 equivalents of a suitable base, such as N-methylmorpholine, in a suitable solvent, such as tetrahydrofuran. The reaction mixture is cooled to a temperature of between $-50^\circ C$ and $0^\circ C$ with $-25^\circ C$ to $-20^\circ C$ being
 15 preferred, before the addition of 1.2 to 1.7 equivalents of isobutyl chloroformate. The reaction is allowed to stir for 30 minutes to 3 hours to allow for the formation of the mixed anhydride, an activated intermediate. While maintaining the temperature at between $-50^\circ C$ and $0^\circ C$, an appropriate free amine of structure (39) or an appropriate R_6' -substituted amines of structure (40) is added. The reaction may, after the addition of amine of structures (39) or (40) is
 20 complete, be warmed to room temperature. The reaction requires from 2 to 48 hours. The product (43) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography, and recrystallization.

Alternatively, for example, an acid of structure (42) is contacted with thionyl chloride or oxalyl chloride to provide an acid chloride intermediate. The reaction is carried out using thionyl chloride or oxalyl chloride as a solvent or the reaction can be carried out in a suitable solvent, such as toluene, benzene, dichloromethane, carbon tetrachloride, or chloroform. The reaction may be carried out in the presence of a suitable catalyst, such as dimethylformamide or pyridine. The reaction is carried out at temperatures of from -40°C to the refluxing temperature of the solvent. The reaction generally requires from 30 minutes to 24 hours. The acid chloride intermediate can be isolated and purified by techniques well known in the art, such as evaporation, extraction, chromatography, and recrystallization.

The acid chloride intermediate is then contacted with an appropriate amine of structures (39) or (40). The reaction is carried out in a suitable solvent, such as toluene, tetrahydrofuran, dimethylformamide, dichloromethane, pyridine, or chloroform. The reaction is carried out in the presence of a slight molar excess of a suitable base, such as triethyl amine, sodium carbonate, potassium bicarbonate, pyridine or diisopropylethyl amine. The reaction is carried out at a temperature of from -70°C to the refluxing temperature of the solvent. The reaction generally requires from 30 minutes to 24 hours. The product of structure (43) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography, and recrystallization.


Alternatively, for example, an acid of structure (42) is contacted with a slight molar excess of an appropriate amine of structures (39) or (40) and 1-hydroxybenzotriazole hydrate in the presence of a slight molar excess of a coupling agent, such as dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC). The reaction is carried out in the presence of a suitable base, such as diisopropylethyl amine. The reaction is carried out in a suitable solvent, such as dichloromethane or chloroform. The product can be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography, and recrystallization.

The compounds of structure (42), and activated intermediates thereof, are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, benzoic acid, 1-naphthoic acid, 2-naphthoic acid, quinaldic acid, 4-pyridazine-carboxylic acid, 4-pyrazolecarboxylic

acid, 2-furoic acid, 3-furoic acid, 2-pyrazinecarboxylic acid, 2-thiophenecarboxylic acid, 4-morpholinecarbonyl chloride, Boc-isonipecotic acid, isonicotinic acid, and picolinic acid are commercially available from Aldrich Chemical Co., Inc and Baychem, Inc.

5 The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^3-Z'^4-(CH_2)_m$ - group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^4 is $NHC(O)NR_6$, can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (45), is set
10 forth in Scheme H wherein all substituents, unless otherwise indicated, are previously defined.

SCHEME H



15

Scheme H provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $Q'^3-Z'^4-(CH_2)_m$ - group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^4 is $NHC(O)NR_6$. All of the other substituents are as defined above.

20

In Scheme H, the compounds of structure (45) are prepared by reacting a free amine of structure (39) or a R_6' -substituted amine of structure (40) with the isocyanate of structure (44). For example, an equivalent of, or a slight molar excess of, an appropriate isocyanate of structure (44) is added to a solution of an appropriate free amine of structure (39) or an
25 appropriate R_6' -substituted amine of structure (40) in a suitable dry aromatic solvent, such as

anhydrous benzene or anhydrous toluene. The mixture is then refluxed for a period of time ranging from 2-24 hours. The appropriate compound of structure (45) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography, and recrystallization.


5

The compounds of structure (44), and activated intermediates thereof, are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, phenyl isocyanate and 1-naphthyl isocyanate are available from Aldrich Chemical Co., Inc. Other compounds of structure (44) which are known in the art include 4-methylphenyl isocyanate, 4-methoxyphenyl isocyanate, 2-naphthyl isocyanate, 4-aminophenyl isocyanate, 4-fluorophenyl isocyanate, 3-chlorophenyl isocyanate, 4-chlorophenyl isocyanate, 3,4-dichlorophenyl isocyanate, 2,6-dimethylphenyl isocyanate, 2-methoxy-1-naphthyl isocyanate, 2,4,6-trimethylphenyl isocyanate and 4-nitrophenyl isocyanate.

15

The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^3-Z'^5-(CH_2)_m$ group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^5 is $OC(O)NR_6$, can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (48), is set forth in Scheme I wherein all substituents, unless otherwise indicated, are previously defined.

20

SCHEME I

5

Scheme I provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $Q'^3-Z'^5-(CH_2)_m$ group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^5 is $OC(O)NR_6$. All of the other substituents are as defined above.

10

In Scheme I, step a, an appropriate free amine of structure (39) or an appropriate R_6 -substituted amine of structure (40) is coupled to the chloroformate of structure (46) in the presence of a suitable solvent, such as toluene, tetrahydrofuran, dimethylformamide, dichloromethane, pyridine, or chloroform. The reaction is carried out in the presence of a slight molar excess of a suitable base, such as triethyl amine, sodium carbonate, potassium bicarbonate, pyridine or diisopropylethyl amine. The reaction is carried out at a temperature of

15

from -70°C to the refluxing temperature of the solvent. The reaction generally requires from 30 minutes to 24 hours. The product of structure (48) can be isolated and purified by techniques well known in the art, such as extraction, evaporation, chromatography, and recrystallization.

5

The chloroformates of structure (46) are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, phenyl chloroformate, benzyl chloroformate, 4-chlorophenyl chloroformate, 4-nitrophenyl chloroformate, 4-methylphenyl chloroformate, 4-bromophenyl chloroformate, 4-fluorophenyl chloroformate, 4-methoxyphenyl chloroformate and chloroformic acid 2-naphthyl ester are available from Aldrich Chemical Co., Inc., or are otherwise known in the art.

10

Alternatively, in Scheme I, step a1, an appropriate free amine of structure (39) or an appropriate R₆'-substituted amine of structure (40) is reacted with the anhydride of structure (47) according to the anhydride coupling procedure described previously in Scheme G.

15


The anhydrides of structure (47) may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. See for example, Pope, B.M. et al., Org. Synth., VI, 418 (1988); Dean, C.S. et al., Chem. Comm., 728 (1969); Tarbell, D.S. et al., Proc. Natl. Acad. Sci. (USA) 69, 730 (1972) or Dean, C.S. et al., J. Org. Chem. 35, 3393 (1970).

20

The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R₁ is a Q'³-Z'⁵-(CH₂)_m- group, wherein Q'³ is as defined in Scheme G, m is defined previously and Z'⁶ is SO₂NR₆, can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (51), is set forth in Scheme J wherein all substituents, unless otherwise indicated, are previously defined.

25

30

SCHEME J

5

Scheme J provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $\text{Q}'^3\text{-Z}'^6\text{-(CH}_2)_m\text{-}$ group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^6 is SO_2NR_6 . All of the other substituents are as defined above.

10

In Scheme J, an appropriate free amine of structure (39) or an appropriate $\text{R}_6\text{'}$ -substituted amine of structure (40) is reacted with the with the chloride of structure (49) or the anhydride of structure (50) according to the anhydride coupling procedure described previously in Scheme G.

15

The chlorides of structure (49) are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, benzenesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, dansyl chloride, 8-quinolinesulfonyl chloride, 2-dibenzofuransulfonyl chloride, 1,2-naphthoquinone-2-diazide-4-sulfonyl chloride, N-morpholinylsulfonyl chloride, N-piperidinylsulfonyl chloride, 2,4,5-trichlorobenzenesulfonyl chloride, 2,5-dichlorobenzenesulfonyl chloride, 2-nitrobenzenesulfonyl chloride, 2,4-dinitrobenzenesulfonyl chloride, 3,5-dichloro-2-hydroxybenzenesulfonyl chloride, 2,4,6-triisopropylbenzenesulfonyl


20

chloride, 2-mesitylenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, 4-chloro-3-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, 4-methoxybenzenesulfonyl chloride, 4-t-butylbenzenesulfonyl chloride, p-toluenesulfonyl chloride, 2,3,4-trichlorobenzenesulfonyl chloride, 2,5-dimethoxybenzenesulfonyl chloride, 4-ethylbenzenesulfonyl chloride, 3,4-dimethoxybenzenesulfonyl chloride, 2,6-dichlorobenzenesulfonyl chloride, 3-bromobenzenesulfonyl chloride, 4-methoxy-2-nitrobenzenesulfonyl chloride and 4-n-butylbenzenesulfonyl chloride are available from Aldrich Chemical Co., Inc., other chemical suppliers, such as Lancaster, Salor, or Maybridge, or are otherwise known in the art.

The anhydrides of structure (50) are commercially available or may be readily prepared by techniques and procedures well known and appreciated by one of ordinary skill in the art. For example, benzenesulfonic anhydride, 4-toluenesulfonic anhydride, 2-mesitylenesulfonic anhydride and 4-nitrobenzenesulfonic anhydride are available from Aldrich Chemical Co., Inc., or are otherwise known in the art.

The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^3-Z'^7-(CH_2)_m$ - group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^7 is $NR_6C(O)$, can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (54), is set forth in Scheme K wherein all substituents, unless otherwise indicated, are previously defined.

-73-

SCHEME K

Scheme K provides a general synthetic procedure for preparing compounds of
 5 structures (15), (16) and (31) wherein R₁ is a Q'³-Z'⁷-(CH₂)_m- group, wherein Q'³ is as defined

in Scheme G, m is defined previously and Z'^7 is $NR_6C(O)$. All of the other substituents are as defined above.

In Scheme K, step a, an appropriate ester of structure (52) is deprotected under
5 conditions well known in the art to provide the acid of structure (53). For example, when R_6' is methyl or ethyl, the ester of structure (52) is dissolved in a suitable organic solvent, such as ethanol and treated with approximately an equal volume of water. To this solution, with stirring is added 1 to 2 equivalents of lithium hydroxide and the reaction is allowed to stir for 1 to 6 hours. The resulting acid is then isolated and purified by techniques well known in the
10 art. For example, the organic solvent is removed under vacuum and the remaining aqueous solution is acidified with dilute hydrochloric acid. The aqueous phase is then extracted with a suitable organic solvent, such as ethyl acetate, and the combined organic extracts are dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue can then be purified by flash chromatography on silica gel with a suitable eluent, such as
15 methanol/chloroform to provide the acid of structure (53).

In Scheme K, step b, the acid of structure (53) is coupled with the amine of structure (53a) under conditions well known in the art to provide the retroamide of structure (54). For example, the acid of structure (53) is dissolved in a suitable organic solvent, such as
20 methylene chloride, under an inert atmosphere, such as nitrogen. The solution is then treated with one to four equivalents of a suitable amine, such as N-methylmorpholine, cooled to about -20°C and one equivalent of isobutylchloroformate is added. The reaction is allowed to stir for about 10 to 30 minutes and 1 to 4 equivalents of the amine of structure (53a) is added to the reaction. The reaction is stirred for 30 minutes to 2 hours at about -20°C and then it is
25 allowed to warm to room temperature and stir for 1 to 3 hours. The retroamide (54) is then isolated and purified by techniques well known in the art, such as extractive techniques and flash chromatography. For example, the reaction is diluted with a suitable organic solvent such as methylene chloride, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by flash chromatography on
30 silica gel with a suitable eluent, such as ethyl acetate/hexane to provide the retroamide (54).


Alternatively, the amine of structure (53a) is dissolved in a suitable anhydrous organic solvent, such as methylene chloride under an inert atmosphere, such as nitrogen. To this

solution is added an equivalent of N-hydroxybenztriazole hydrate, an equivalent of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and an equivalent of the acid of structure (53), dissolved in a suitable anhydrous organic solvent, such as methylene chloride. The reaction is then allowed to stir for about 1 to 15 hours. The retroamide of structure (54) is then isolated and purified by techniques well known in the art, such as extractive techniques and flash chromatography. For example, the reaction is diluted with a suitable organic solvent, such as ethyl acetate, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by flash chromatography on silica gel with a suitable eluent, such as ethyl acetate/hexane to provide the retroamide (54).

10

The cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) where R_1 is a $Q'^3-Z'^8-(CH_2)_m$ - group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^8 is $HNC(O)O$, can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (56), is set forth in Scheme L wherein all substituents, unless otherwise indicated, are previously defined.

15

SCHEME L


- 5 Scheme L provides a general synthetic procedure for preparing compounds of structures (15), (16) and (31) wherein R_1 is a $Q'^3-Z'^8-(CH_2)_m-$ group, wherein Q'^3 is as defined in Scheme G, m is defined previously and Z'^8 is $HNC(O)O$. All of the other substituents are as defined above.

In Scheme L, step a, an appropriate ester of structure (52) is reduced under conditions well known in the art to provide the alcohol of structure (55). For example, the ester of structure (52) is dissolved in a suitable solvent, such as hexane, dichloromethane, tetrahydrofuran or toluene, with tetrahydrofuran being preferred, and contacted with a suitable
5 reducing agent, such as lithium borohydride, sodium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, 9-borabicyclo[3.3.1]nonane, preferably lithium borohydride. The reaction is carried out by either adding a solution of an appropriate ester (52) to a solution of an appropriate reducing agent or by adding a solution of an appropriate reducing agent to a solution of an appropriate ester of structure (52). The addition is carried out at a temperature
10 of from about -30°C to about 10°C. The reaction is carried out at a temperature of from about 0°C to about 30°C. The reaction generally requires from 2 to 5 hours. The product can be isolated by quenching and extraction. The quench is carried out at a temperature of from about -15°C to about 0°C. The alcohol of structure (55) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The alcohol of structure
15 (55) can be purified as is well known in the art by chromatography and distillation.

In Scheme L, step b, the alcohol of structure (55) is reacted with the isocyanate of structure (44) according to the procedures set forth in Scheme H above to afford the appropriate compound of structure (56).
20

Alternatively, the cis α -thioamide of structure (15), the trans α -thioamide of structure (16), and the α -thioamide of structure (31) can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art. An alternate general synthetic scheme for preparing these compounds is set forth in Scheme M wherein all substituents,
25 unless otherwise indicated, are previously defined.

-78-

SCHEME M

5

Scheme M provides an alternate general synthetic procedure for preparing compounds of structures (15), (16) and (31). All of the substituents are as defined above.

In Scheme M, step a, the thiol of structure (57a) in a suitable organic solvent such as dimethylformamide, is degassed and treated with ethyl bromoacetate (57b) and a suitable

10



tertiary amine such as diisopropyl ethyl amine. The reaction mixture is placed in a cooling bath and stirred for a period of time ranging from about 20 minutes to about 1 hour whereupon a precipitate is observed. The cooling bath is then removed and the reaction mixture is stirred for an additional 48 to 72 hours. The sulfide ester of structure (57) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The sulfide ester of structure (57) can be purified as is well known in the art by chromatography and distillation.

In Scheme M, step b, the sulfide ester of structure (57) in a suitable organic solvent such as tetrahydrofuran is treated with an amide base such as lithium bis(trimethylsilyl)amide. The resulting intermediate is then reacted with an R_1 -substituted alkyl halide (R_1CH_2-Hal) to yield the R_1 -substituted sulfide ester of structure (58). The R_1 -substituted sulfide ester of structure (58) can be isolated by methods well known and appreciated in the art, such as extraction and evaporation. The R_1 -substituted sulfide ester of structure (58) can be purified as is well known in the art by chromatography and distillation.


In Scheme M, step c, the R_1 -substituted sulfide ester of structure (58) is deprotected to yield the R_1 -substituted sulfide acid of structure (59) according to the procedure described in Scheme K, step a.

In Scheme M, step d, the R_1 -substituted sulfide acid of structure (59) is coupled with an appropriate compound of structures (11), (12) or (29) to provide an appropriate compound of structures (15), (16) or (31) according the procedures described in Scheme G.

The compounds of formula (1) wherein R_8 is a $-C(O)-(CH_2)_q-K$ group can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art, as disclosed in U.S. Pat. No. 5,424,425, issued Jun. 13, 1995. A general synthetic scheme for preparing these compounds, signified as the compounds of structure (61), is set forth in Scheme N wherein all substituents, unless otherwise indicated, are previously defined.

SCHEME N


5 Scheme N provides a general synthetic procedure for preparing compounds of structure (61) wherein K' is



R_7'' represents Boc, C_1 - C_4 alkyl or a $-(\text{CH}_2)_p\text{-Ar}_2$ group. All of the other substituents are as defined above.

In Scheme N the appropriate thioacetyl compound of structure (61) can be prepared by reacting the appropriate bromoamide of structure (13), (14) or (30) with the appropriate triphenylmethyl aminothiоacetate of structure (60 or 60a) under basic conditions such as sodium hydride, hydrogen sulfide in a suitable aprotic solvent such as dimethylformamide.


For those thioacetyl compounds of structure (61) wherein K' is




10

wherein R₃'' is Boc, the Boc protecting group can be removed using trifluoroacetic acid to give the corresponding compounds where R₇ is hydrogen.

In addition, the sulfide functionality of those thioacetyl compounds of structure (61) wherein K is



may be oxidized by techniques and procedures well known in the art, such as magnesium monoperoxyphthalic acid hexahydrate to give the thioacetyl compounds of structure (61) wherein K is




25 wherein p' is 1 or 2.

Scheme O provides a general synthetic scheme for preparing the triphenylmethyl aminothioliacetates of structures (60) and (60a).

SCHEME O



5



Scheme O provides a general synthetic procedure for preparing compounds of structure (64) and (64a) wherein K'' is

10

-83-

and K''' is


R_7'' represents Boc, C_1 - C_4 alkyl or a $-(\text{CH}_2)_p\text{—Ar}_2$ group. All of the other substituents are as defined above.

In Scheme O, step a, a triphenylmercaptan (62) and bromoacetyl bromide (63) are reacted under basic conditions, such as pyridine, in an aprotic solvent, such as methylene chloride to give triphenylmethylbromothioloacetate of structure (64).

In Scheme O, step b, triphenylmethyl bromothioloacetate of structure (64) is reacted with the appropriate amino compound of structure (65) under basic conditions, such as pyridine, in an aprotic solvent such as methylene chloride to give the appropriate triphenylmethyl aminothioloacetate compound of structure (66).


In Scheme O, optional step c, the sulfide functionality of those thioacetyl compounds of structure (66) wherein K is

-84-



may be oxidized by techniques and procedures well known in the art, such as magnesium monoperoxyphthalic acid hexahydrate to give the thioacetyl compounds of structure (66a)



5 wherein K is



wherein p' is 1 or 2.

10

Alternatively, the compounds of formula (1) wherein R₈ is a -C(O)-(CH₂)₄-K group may be prepared as described in Scheme P. In Scheme P, all substituents are as previously defined unless otherwise indicated.

SCHEME P

5 Scheme P provides a general synthetic procedure for preparing compounds of structure (61) wherein all of the substituents are as previously defined.


10 In Scheme P, the thiol functionality of the thiol compounds of structures (17), (18) or (32) is coupled with the appropriate acid of structure (68) in the presence of a suitable coupling agent to give the appropriate thioacetyl compound of structure (61). For example, the appropriate thiol compound of structures (17), (18) or (32) can be reacted with the appropriate acid of structure (68) in the presence of a coupling agent such as 2-fluoro-1-methylpyridinium p-toluenesulfate, EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), carbonyldiimidazole, EEDQ (1-ethoxycarbonyl-2-ethoxy-1,2-

15 dihydroquinoline, DCC, or diethylcyanophosphonate in a suitable aprotic solvent such as methylene chloride to give the appropriate thioacetyl compound of structure (61).

20 The compounds of formula (1) wherein R₈ is a -S-G group can be synthesized according to techniques well known and appreciated by one of ordinary skill in the art, as disclosed in PCT Int. Publ. No. WO 95/21839, published Aug. 17, 1995. A general synthetic

scheme for preparing these compounds, signified as the compounds of structure (71), is set forth in Scheme Q wherein all substituents, unless otherwise indicated, are previously defined.

SCHEME Q



The disulfides of structure (69) can be obtained by methods known in the art or by methods known analogously in the art, Roques, B.P. et al., *J. Med. Chem.* 33, 2473-2481 (1992).

In Scheme Q, an appropriate disulfide of structure (69) is contacted with an appropriate thiol of structures (17), (18) or (32) to give a disulfide of structure (70) or a protected form thereof. An appropriate disulfide of structure (70) is one in which G is as desired in the final product of formula (1) or gives rise upon deprotection to G as is desired in the final product of formula (1).

For example, an appropriate disulfide of structure (69) is contacted with an appropriate thiol of structures (17), (18) or (32). The reaction is carried out in a suitable solvent, such as ethanol, methanol, dichloromethane, or mixtures of ethanol or methanol and dichloromethane. The solvent is degassed by passing a stream of nitrogen gas through it for 15 minutes before



the reaction is carried out. The reaction is carried out using from 1.0 to 4.0 molar equivalents of an appropriate compound of structure (69). The reaction is carried out at temperatures of from 0°C to the refluxing temperature of the solvent, with a temperature of 10°C to 30°C being preferred. The reaction generally requires from 1 to 48 hours. The product can be
5 isolated by techniques well known in the art, such as extraction, evaporation, and precipitation. The appropriate disulfide or protected disulfide of structure (70) can be purified by chromatography and recrystallization.

The protected disulfides of structure (70) can be deprotected according to techniques
10 well known in the art. The selection, use and removal of protecting groups and the removal of protecting groups in a sequential manner utilizing suitable protecting groups such as those described in Protecting Groups in Organic Synthesis by T. Greene is well known and appreciated by those skilled in the art.

15 The following examples present typical syntheses as described in Schemes A through Q. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. As used herein, the following terms have the indicated meanings: "g" refers to grams; "mol" refers to moles; "mmol" refers to millimoles; "L" refers to liters; "mL" refers to milliliters; "bp" refers to boiling point; "°C" refers to
20 degrees Celsius; "mm Hg" refers to millimeters of mercury; "mp" refers to melting point; "mg" refers to milligrams; "μM" refers to micromolar; "μg" refers to micrograms; "h" or "hrs." refers to hours, "min" refers to minutes; "HOBt" refers to hydroxybenzotriazole; "EDC" refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; "NCEP" refers to N-carbethoxy phthalimide; and "MTBE" refers to methyl:tert-butyl ether.

EXAMPLE 1


Preparation of 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-5-phenyl-1*H*-azepin-3-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [3*S*-[1(*R**), 3 α , 5 α]]- ; Compound II-1 (MDL 108,180)

STEP 1.1:

10

Scheme C, step a; Cool a solution of Boc-Phe-OH (8.00 g, 30.2 mmol) in tetrahydrofuran to -30°C and treat sequentially with *N*-methylmorpholine (3.5 mL, 32 mmol) and isobutyl chloroformate (4.5 mL, 35 mmol). After 10 min, treat the reaction mixture with 40% aqueous methylamine (13 mL, 380 mmol), stir for 2 hours, and concentrate. Dissolve the residue in methylene chloride (125 mL) and wash with 1*N* hydrochloric acid and saturated NaHCO₃ (75 mL each). Dry the organic layer (NaSO₄) and concentrate to give crude title compound, which is used without further purification.


15

STEP 1.1.1:

5

Scheme C, step b; Stir a solution of the crude product of Example 1.1 in methylene chloride (100 mL) and trifluoroacetic acid (20 mL) at ambient temperature for 3 hours and concentrate. Remove residual trifluoroacetic acid by coevaporation with carbon tetrachloride and toluene using a rotary evaporator. Triturate the sticky residue with diethyl ether to yield the title compound as a white solid (9.12 g, 100%).

10

STEP 1.2:


15

Scheme D, step a; Treat 6-aminocaproic acid (8.0 g, 60 mmol) in H₂O (100 mL) with Na₂CO₃ (6.84 g, 64 mmol) and NCEP (14.0 g, 64 mmol). Stir the reaction mixture at ambient temperature for 90 min and extract with ethyl acetate (100 mL). Cool the aqueous layer in an ice bath and acidify to pH ~ 1 using concentrated hydrochloric acid. Collect the white

precipitate by filtration, wash with water, and dry in a vacuum oven overnight to give 6-phthalimidocaproic acid (12.7 g, 80% yield).

STEP 1.2.1:


5



Scheme D, step b; Treat dropwise a mixture of 6-phthalimidocaproic acid (12.7 g, 48 mmol) and dry red phosphorous (1.95 g, 63 mmol) with bromine (12.7 mL, 246 mmol) at 0°C. Warm the resulting lumpy mixture to room temperature and heat to 80°C for 3 hours. Cool the reaction mixture to room temperature, pour into water (300 mL) containing NaHSO₃, and neutralize using solid NaHCO₃. Wash the aqueous layer with diethyl ether (150 mL) and acidify with concentrated hydrochloric acid. Collect the pale yellow precipitate by filtration and dry to give 2-bromo-6-phthalimidocaproic acid (15 g, 91.5% yield).

15

STEP 1.3:




20


Scheme A, step a; A solution of diisopropylamine (16.2 mL, 116 mmol) in tetrahydrofuran (100 mL) at 0°C is treated dropwise with n-butyllithium (44 mL, 110 mmol, 2.5M-hexanes). Stir for 30 min. Cool the solution to -78°C and add a solution of 4-

phenylcyclohexanone (17.42 g, 100 mmol) in tetrahydrofuran (40 mL) using a cannula. After 1 hour, quench the reaction with chlorotrimethylsilane (14 mL, 110 mmol). Stir the mixture for 45 min, and remove the cooling bath. After 2 hours, pour the reaction mixture into ice water (100 mL) and saturated aqueous NaHCO_3 solution (100 mL). Extract the mixture with pentanes (300 mL). Wash the organic layer with brine (150 mL), dry (Na_2SO_4), and concentrate to yield the silyl enol ether as a pale yellow oil (25.6 g, 104%).


Dissolve the crude silyl enol ether from above in a methylene chloride (200 mL)/methanol (300 mL) solvent mixture, cool to -78°C , and treat with ozone until a blue color persists (55 min). Purge excess ozone from the system by bubbling argon through the solution for 20 min. Add dimethyl sulfide (40 mL, 540 mmol), and allow the reaction mixture to warm gradually to ambient temperature overnight. After 16 hours, concentrate the solution to about 150 mL, and add trimethyl orthoformate (50 mL, 460 mmol) and acetyl chloride (10 mL, 140 mmol). Heat the mixture at reflux for 4 hours and cool to ambient temperature. Add a solution of potassium hydroxide (22 g, 600 mmol) in water (100 mL). Heat the reaction mixture at 60°C for 2 hours, cool to ambient temperature, concentrate and partition between MTBE (2 x 125 mL) and water (75 mL). Cool the aqueous layer in an ice bath and acidify to $\text{pH} = 1 - 2$ using concentrated aqueous hydrochloric acid. Extract with methylene chloride (250 mL). Wash the organic layer with brine (75 mL), dry (Na_2SO_4), and concentrate to afford the title compound as a pale orange oil (20.3 g, 80% overall).

STEP 1.3.1:

Scheme A, step b; Treat the product of Example 1.3 (16.0 g, 63.4 mmol) in
5 tetrahydrofuran (200 mL) with triethylamine (10.6 mL, 76.1 mmol) and cool to -78°C . Add
trimethylacetyl chloride (8.6 mL, 70 mmol) dropwise. After 15 min, transfer the mixture to an
ice bath for 45 min, then recool to -78°C . Treat the resulting slurry via cannula with a solution
of lithiated auxially which is prepared by adding *n*-butyllithium (28.4 mL, 71.0 mmol, 2.5 M-
hexanes) to (*S*)-4-benzyl-2-oxazolidinone (12.94 mL, 73.0 mmol) in tetrahydrofuran (200 mL)
10 cooling to -78°C and stirring for 1 hour. Allow the reaction mixture to warm gradually to
ambient temperature overnight. After 18 hours, add water (5 mL) and concentrate the
solution. Partition the residue between saturated aqueous ammonium chloride solution (75
mL) and methylene chloride (200 + 125 mL). Dry the organic layer (Na_2SO_4) and concentrate.
Purify the crude product by flash chromatography using hexanes: ethyl acetate (3:1 to 3:2) to
15 afford the desired acyloxazolidinone as a light tan oil (22.13 g, 85%).


STEP 1.3.2:

Scheme A, step c; Cool a solution of potassium bis(trimethylsilyl)amide (58 mL, 29
5 mmol, 0.5 M-toluene) in tetrahydrofuran (50 mL) to -78°C and treat dropwise via cannula
with a solution of acyloxazolidinone (10.58 g, 25.71 mmol) in tetrahydrofuran (100 mL),
precooled to -78°C . After 30 min, add a solution of triisopropylbenzenesulfonyl azide (9.90 g,
32 mmol) in tetrahydrofuran (50 mL), precooled to -78° over 10 min using a cannula. Stir the
solution for 3 min, quench with acetic acid (6.9 mL, 120 mmol), stir for 5 min, and transfer to
10 an oil bath (35°C). After 1.5 h, cool the suspension to ambient temperature, and add water to
obtain a solution. Concentrate the solution, and partition the residue between saturated
aqueous ammonium chloride solution (75 mL) and ethyl acetate (350 mL). Wash the organic
layer with saturated aqueous NaHCO_3 :brine (1:1 = 75 mL), dry (Na_2SO_4) and concentrate.
Triturate the residue with chloroform/methylene chloride and filter. Concentrate the filtrate,
15 and purify the crude material by flash chromatography using hexanes:ethyl acetate (3:1 to 3:2)
to afford the desired α -azidoacyloxazolidinone as a pale yellow oil (9.96 g, 86%).


STEP 1.3.3:

5 Scheme A, step d; Cool α -azidoacyloxazolidinone (9.86 g, 21.8 mmol) in tetrahydrofuran (300 mL)/water (90 mL) in an ice bath and treat sequentially with 30% aqueous H_2O_2 (8.8 mL, 77 mmol) then lithium hydroxide (1.05 g, 43.8 mmol). Stir the mixture for 1.5 h at ambient temperature and add Na_2SO_3 (12 g, 95 mmol) in water (68 mL). Remove the tetrahydrofuran using a rotary evaporator. Extract the aqueous layer with diethyl
10 ether (2 x 125 mL), cooled in an ice bath, acidified to pH 1-2 using 6 N HCl, and extract with methylene chloride (2 x 200 mL). Dry the organic layer (Na_2SO_4) and concentrate to afford the desired acid as a pale yellow oil (7.19 g, 112%).


15 Treat sequentially the so formed α -azidoacid (21.8 mmol) in tetrahydrofuran (120 mL) at ambient temperature with 2-trimethylsilylethanol (9.4 mL, 66 mmol), pyridine (5.3 mL, 66 mmol), and EDC (8.40 g, 44 mmol). Stir the mixture for 2.5 days and concentrate. Dissolve the mixture in MTBE (150 mL), and wash the solution sequentially with 5% aqueous sulfuric acid, saturated NaHCO_3 , and brine (50 mL each). Dry the organic layer (Na_2SO_4) and concentrate. Purify the residue by flash chromatography using hexanes:ethyl acetate (7:1 to
20 6:1) to afford the title compound as a colorless oil (7.09 g, 83%).

STEP 1.3.4:


- 5 Scheme A, step e; Heat a solution of the product of example 1.3.3 (3.00 g, 7.62 mmol) in acetic acid (30 mL), water (10 mL), and tetrahydrofuran (10 mL) in an oil bath at 60°C for 4 h. Cool the solution to ambient temperature and concentrate using a rotary evaporator (bath temperature = 40°C). Partition the residue between MTBE (125 mL) and brine (50 mL). Wash the organic layer with saturated aqueous NaHCO₃:brine (1:1 = 50 mL), dry (Na₂SO₄)
- 10 and concentrate. Purify the residue by flash chromatography using hexanes:ethyl acetate (6:1) to afford the title compound as a colorless oil (2.52 g, 95%).

STEP 1.3.5:

- Scheme A, step f; Treat a solution of the product of example 1.3.4 (717 mg, 2.06 mmol) and the amine salt product of Step 1.1.1 (1.81 g, 6.19 mmol) in methanol (20 mL) with powdered activated 3A sieves. After 30 min, add sodium cyanoborohydride (0.73 mL, 0.73 mmol, 1.0M-THF). Stir the reaction mixture for 2.5 h, filter through a pad of Celite®, and concentrate. Dissolve the residue in methylene chloride (100 mL) and wash with saturated aqueous NaHCO_3 :brine (1:1 = 30 mL). Dry the organic layer (Na_2SO_4) and concentrate.
- Purify the product mixture by flash chromatography using hexanes:ethyl acetate (1:1 to 1:2) to afford the title compound as a viscous colorless oil (737 mg, 70%).


STEP 1.3.6:

- 5 Scheme A, step g; Treat a solution of the product of example 1.3.5 (737 mg, 1.45 mmol) in tetrahydrofuran (15 mL) at ambient temperature with tetra-*n*-butylammonium fluoride (2.2 mL, 2.2 mmol, 1.0M-THF) and stir. After 3 h, concentrate the solution. Dissolve the residue in ethyl acetate (125 mL) and wash with 10% aqueous HCl (30 mL) and brine (25 mL). Dry the organic layer (Na₂SO₄) and concentrate to yield crude amino acid
- 10 (0.72 g, 122%). Dissolve this material in tetrahydrofuran (27 mL), cool in an ice bath, and treat sequentially with *N*-methylmorpholine (0.35 mL, 3.2 mmol) and isobutyl chloroformate (0.24 mL, 1.85 mmol). Stir the suspension for 2.5 h and filter. Wash the salts with dry tetrahydrofuran and concentrate the filtrate. Purify the residue by radial chromatography using hexanes:ethyl acetate (1:1 to 2:3) to afford separately, the *cis*- (230 mg, 41%) and *trans*- (290
- 15 mg, 51%) isomers of the title compound.

STEP 1.3.7:


- 5 Scheme A, step h1; Degas (vacuum- N_2) a solution of the *cis*-isomer of the product of example 1.3.6 (145 mg, 0.370 mmol) in methanol (6 mL) and treat with 1,3-propanedithiol (0.20 mL, 1.99 mmol) and triethylamine (0.27 mL, 1.94 mmol). Stir the solution for 66 h and concentrate. Purify the residue by flash chromatography using methylene chloride:methanol (100:0, then 95:5 to 90:10) to afford the title compound as a colorless oil (140 mg, 104%).

10

STEP 1.3.8:

Scheme A, step i1; Stir a mixture of the product of example 1.3.7 (135 mg, 0.370 mmol), 2-bromo-6-phthalimidocaproic acid (189 mg, 0.56 mmol, example 1.2.1), EDC (106 mg, 0.55 mmol) and HOBt (75 mg, 0.56 mmol) in methylene chloride (8 mL) at ambient temperature for 18 h. Concentrate the reaction mixture and partition between ethyl acetate (60 mL) and 5% aqueous sulfuric acid (15 mL). Wash the organic layer with saturated NaHCO₃, then brine (15 mL each), dry (Na₂SO₄), and concentrate. Purify the crude product by flash chromatography using hexanes:ethyl acetate (2:3 to 1:3) to afford the title compound as a white foam (220 mg, 87%).


STEP 1.3.9:



Scheme A, step j1; Degas (vacuum-N₂) a solution of p-methoxybenzylmercaptan (0.09 mL, 0.65 mmol) in dimethylformamide (3 mL) and treat with sodium hydride (20 mg, 0.50 mmol, 60% oil dispersion). After 1 h, add a solution of the product of example 1.3.8 (220 mg, 0.320 mmol) in dimethylformamide (2 mL + 3 mL wash) to the mercaptide using a cannula. Add a spatula tip of tetra-n-butylammonium iodide as a catalyst. Stir the reaction mixture for 20 h and add saturated aqueous ammonium chloride solution (25 mL) and water (5 mL). Extract the solution with ethyl acetate (75 mL) and wash the organic layer with brine (25 mL).

Back-extract the combined aqueous layers with ethyl acetate (50 mL). Dry the combined organic layers (Na_2SO_4), concentrate, and place under high vacuum. Purify the crude product by flash chromatography using methylene chloride:ethyl acetate (2:1 to 1:2) to afford the title compound as a white foam (194 mg, 80%).

5

STEP 1.3.10:

10 Scheme A, step k1; Cool a mixture of the product of example 1.3.9 (194 mg, 0.255 mmol), mercuric acetate (102 mg, 0.32 mmol), and anisole (0.28 mL, 2.55 mmol) in methylene chloride (8 mL) in an ice bath, degas (vacuum- N_2) and treat with trifluoroacetic acid (2.5 mL). After 4 h, bubble H_2S gas through the reaction mixture for 15 min. Filter the black precipitate and wash with methylene chloride. Concentrate the filtrate and remove
15 residual trifluoroacetic acid by coevaporation with carbon tetrachloride. Triturate the residue with hexanes to yield the title compound (MDL 108,180) as a light tan solid (150 mg, 92%).
IR(KBr) 702, 721, 752, 962, 1045, 1173, 1209, 1366, 1398, 1437, 1494, 1643, 1711, 1773, 2862, 2940, 3028, 3380 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.34-1.81 (m, 6), 1.87-2.11 (m, 4), 2.82 (d, 3, $J = 4.9$), 2.90-3.06 (m, 2), 3.13-3.34 (m, 3), 3.48 (dd, 1, $J = 11, 16$), 3.67 (t, 2, $J = 7.3$), 3.69-


3.76 (m, 1), 4.59-4.66 (m, 1), 5.03 (t, 1, $J = 8.1$), 6.32-6.39 (m, 1), 7.00-7.03 (m, 2), 7.15-7.35 (m, 8), 7.60-7.65 (m, 1), 7.68-7.73 (m, 2), 7.78-7.84 (m, 2).

MW Calcd for $C_{36}H_{40}N_4O_5S = 640.8$.

5 Found $(M+H^+) = 641$.


EXAMPLE 2

10 Preparation of 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-5-phenyl-1*H*-azepin-3-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [3*S*-[1(*R**), 3 α , 5 β]]-; Compound III-1 (MDL 106,540)




15

STEP 2.1:




Scheme A, step h2; Prepare by the method of example 1.3.7 using the *trans*-isomer of example 1.3.6 (290 mg, 0.740 mmol). Purify by flash chromatography using methylene:methanol (100:0, then 95:5 to 90:10) to give the title compound (249 mg, 92%).


5

STEP 2.2:

Scheme A, step i2; Stir a mixture of the product of example 2.1 (125 mg, 0.342 mmol), 2-bromo-6-phthalimidocaproic acid (189 mg, 0.56 mmol), EDC (106 mg, 0.55 mmol) and HOBT (75 mg, 0.56 mmol) in methylene chloride (8 mL) at ambient temperature for 17 h. Concentrate the reaction mixture and partition between ethyl acetate (60 mL) and 5% aqueous sulfuric acid (20 mL). Wash the organic layer with saturated aqueous NaHCO₃:brine (1:1 = 20 mL), dry (Na₂SO₄), and concentrate. Purify the crude product by flash chromatography using hexanes:ethyl acetate (2:3 to 1:2) to afford the title compound as a white foam (187 mg, 80%).

STEP 2.3:

Scheme A, step j2; Degas a solution of the product of example 2.2 (150 mg, 0.22
5 mmol), p-methoxybenzylmercaptan (0.08 mL, 0.57 mmol), and tetra-n-butylammonium iodide (spatula tip, catalyst), in dimethylformamide (3 mL) and treat at ambient temperature with cesium carbonate (94 mg, 0.29 mmol). After 24 h, add saturated aqueous ammonium chloride solution (20 mL) and water (5 mL). Extract the solution with ethyl acetate (75 mL), and wash the organic layer with brine (2 x 20 mL). Dry (Na₂SO₄) the combined organic layer,
10 concentrate, and place under high vacuum. Purify the crude product by flash chromatography using hexanes:ethyl acetate (2:3 to 1:2) to give the title compound as a white foam (160 mg, 77%).

STEP 2.4:



Scheme A, step k2; Cool a mixture of the product of example 2.3 (160 mg, 0.210
 5 mmol), mercuric acetate (84 mg, 0.26 mmol), and anisole (0.23 mL, 2.10 mmol) in methylene
 chloride (6.6 mL) in an ice bath, degas and treat with trifluoroacetic acid (3 mL). After 4 h,
 bubble H₂S gas through the reaction mixture for 15 min. Filter the black precipitate and wash
 with methylene chloride. Concentrate the filtrate and remove residual trifluoroacetic acid by
 coevaporation with carbon tetrachloride. Purify the residue by flash chromatography using
 10 hexanes:ethyl acetate (1:1 to 1:2) to yield the title compound (MDL 106,540) as a light tan
 solid (96 mg, 71%). IR(KBr) 702, 721, 1337, 1366, 1398, 1437, 1454, 1468, 1497, 1530,
 1645, 1678, 1710, 1770, 2938, 3380 cm⁻¹; ¹H NMR (CDCl₃) δ 1.35-1.80 (m, 7), 1.94-2.10 (m,
 2), 1.96 (d, 0.5, J = 8.7), 1.97 (d, 0.5, J = 8.8), 2.50-2.70 (m, 2), 2.81 (d, 1.5, J = 4.8), 2.82 (d,
 1.5, J = 4.8), 2.91-3.00 (m, 1), 3.22-3.29 (m, 1), 3.31-3.39 (m, 1), 3.47-3.58 (m, 1), 3.67 (t, 2, J
 15 = 7.2), 3.72-3.80 (m, 1), 4.82-4.90 (m, 1), 5.25 (t, 1, J = 7.8), 6.07-6.10 (m, 1), 7.15-7.30 (m,
 10), 7.48-7.55 (m, 1), 7.66-7.72 (m, 2), 7.78-7.84 (m, 2).

MW Calcd for C₃₆H₄₀N₄O₅S = 640.8.

Found (M+H)⁺ = 641.


EXAMPLE 3

Preparation of 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-4-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-5-oxo-1-(phenylmethyl)-1*H*-1,4-diazepin-6-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [6*S*-[4(*R**), 6*R**(*R**)]]-, Compound IV-1

STEP 3.1:

Scheme B, step b; A solution of *N*-*tert*-butoxycarbonyl-L-serine β -lactone (1.00 g, 5.82 mmol; Pansare, S.V. et al., Org. Synth. 70, 10 (1991)) in CH_3CN (100 mL) is added dropwise over 1.5 h to a solution of allyl amine (10 mL, 133 mmol) in CH_3CN (200 mL).

After 1 h, the solution is concentrated, and the solid residue is triturated with CH_3CN to afford the desired amino acid as a white solid (648 mg, 46%). The filtrate is concentrated to yield the hydroxyamide byproduct as a white solid (632 mg, 44%).

STEP 3.2

5 Scheme B, step c; A solution of the amino acid product of Step 3.1 (640 mg, 2.62 mmol) in saturated aqueous NaHCO_3 (7.5 mL) and water (1 mL) is treated at ambient temperature with a solution of benzyl chloroformate (0.42 mL, 2.94 mmol) in acetone (1 mL) over 5 min. The cloudy reaction mixture is stirred for 2 h. The resulting solution is partitioned between MTBE (40 mL) and water (25 mL). The aqueous layer is cooled in an ice bath, brought to about pH 2 using 5% aqueous HCl, saturated with NaCl, and extracted with methylene chloride (2 X 45 mL). The combined organic layers are dried (Na_2SO_4) and concentrated to give the CBz-protected amino acid as a colorless oil (1.14 g). A solution of the CBz-protected amino acid (1.14 g) in methylene chloride (100 mL) and trifluoroacetic acid (20 mL) is stirred at ambient temperature for 1 h and concentrated. Residual trifluoroacetic acid is removed by coevaporation with carbon tetrachloride using a rotary evaporator to give the amino acid tfa salt (1.27 g).

10

15

A solution of the amino acid tfa salt (1.27 g) in water (25 mL), dioxane (10 mL) and solid Na_2CO_3 (306 mg, 2.88 mmol) is treated with NCEP (945 mg, 4.32 mmol) and stirred at 40°C. After 4 h, additional Na_2CO_3 (306 mg) is added to bring the mixture from about pH 4 to about pH 8-10. NCEP (630 mg, 2.87 mmol) is added, and the reaction mixture is stirred for 16 h and concentrated. Water (40 mL) is added and the mixture is extracted with MTBE (40 mL). The aqueous layer is cooled in an ice bath, acidified to about pH 1 with 6N HCl, and extracted with methylene chloride (60 mL) then ethyl acetate (60 mL). The organic layer is dried (Na_2SO_4) and concentrated. The product mixture is purified by flash chromatography


20

25

using hexanes: ethyl acetate: acetic acid (1:1:0.1) to afford the desired phthalimido acid (1.2 g).

STEP 3.3


5




Scheme B, step d; The phthalimido acid product of Step 3.2 (1.2 g) in tetrahydrofuran (25 mL) and methylene chloride (10 mL) is treated sequentially at ambient temperature with 2-trimethylsilylethanol (1.2 mL, 8.4 mmol), pyridine (0.68 mL, 8.4 mmol), and EDC (1.26 g, 6.55 mmol). The mixture is stirred 18 h and concentrated. The residue is dissolved in MTBE (75 mL), and the solution is washed sequentially with 5% aqueous sulfuric acid and saturated aqueous NaHCO₃:brine = 1:1 (40 mL each). The organic layer is dried (Na₂SO₄) and concentrated. The residue is purified by flash chromatography using methylene chloride:ethyl acetate (100:0 to 95:5) to afford the desired ester as a colorless oil (1.12 g, 84% overall).

10


15

STEP 3.4


- 5 Scheme B, step e; A solution of the ester product of Step 3.3 (1.12 g, 2.20 mmol) in methylene chloride (30 mL) and methanol (3 mL) is cooled to -78°C under argon. Ozone is passed through the solution until a blue color persists. The excess ozone is purged by bubbling argon through the solution for 15 min. Dimethyl sulfide (3 mL) is added and the solution is allowed to warm gradually to ambient temperature overnight. After 15 h, the
- 10 reaction mixture is diluted with methylene chloride (100 mL) and washed with brine (40 mL). The organic layer is dried (Na₂SO₄) and concentrated. The product mixture is purified by flash chromatography using hexanes:ethyl acetate (3:2 to 1:1) to afford the desired aldehyde (1.11 g, 99%).

STEP 3.5


- 5 Scheme B, step f; A solution of aldehyde (1.11 g, 2.17 mmol) and amine salt product of Step 1.1.1 (1.84 g, 6.29 mmol) in methanol (23 mL) is stirred 10 min and treated with sodium cyanoborohydride (2.2 mL, 2.2 mmol, 1.0M-THF). The reaction mixture is stirred 3 h and concentrated. The residue is dissolved in methylene chloride (1250 mL) and washed with saturated aqueous NaHCO₃:brine (1:1 = 40 mL). The organic layer is dried (Na₂SO₄) and
- 10 concentrated. The product mixture is purified by flash chromatography using hexanes:ethyl acetate (3:2 to 1:2) to afford the desired amino-ester as a white foam (1.32 g, 90%).

STEP 3.6


- 5 Scheme B, step g; A solution of the silyl ester product of Step 3.5 (1.30 g, 1.93 mmol)
in tetrahydrofuran (20 mL) is treated at ambient temperature with tetra-n-butylammonium
fluoride (3.0 mL, 3.0 mmol, 1.0M-THF) and stirred. After 1.5 h, the solution is concentrated.
The residue is dissolved in ethyl acetate (125 mL) and washed with 10% aqueous hydrochloric
acid (30 mL) and brine (25 mL). The organic layer is dried (Na₂SO₄) and concentrated to
10 yield crude amino acid (1.54 g). This material is dissolved in tetrahydrofuran (36 mL), cooled
in an ice bath, and treated sequentially with N-methylmorpholine (0.47 mL, 4.27 mmol) and
isobutylchloroformate (0.32 mL, 2.47 mmol). The suspension is stirred for 4 h and filtered
through a pad of Celite[®]. The salts are washed with dry tetrahydrofuran, and the filtrate is
concentrated. The residue is purified by flash chromatography using hexanes: ethyl acetate
15 (3:2 to 1:1) to afford the lactam (954 mg, 89%).

STEP 3.7

- 5 Scheme B, step h; A solution of the Z-lactam product of Step 3.6 (954 mg, 1.72 mmol) in methanol (17 mL) is degassed (vacuum-N₂), treated with 10% Pd-C (500 mg), and stirred under a H₂ atmosphere (balloon) for 15 h. Additional catalyst (250 mg) is added, the mixture is stirred 7 h, degassed and filtered. The filtrate is concentrated to yield the desired product (720 mg, 100%).

STEP 3.8

- 5 Scheme B, step i; A solution of the amine product of Step 3.7 (720 mg, 1.71 mmol) in CH_3CN (10 mL) and dimethylformamide (3 mL) is treated with benzyl bromide (0.30 mL, 2.5 mmol) and solid K_2CO_3 (130 mg, 0.94 mmol). After 18 h, the mixture is concentrated, and the residue is partitioned between ethyl acetate (75 mL) and water (15 mL). The organic layer is dried (Na_2SO_4) and concentrated. The product mixture is purified by flash chromatography
- 10 using hexanes:ethyl acetate (1:2) to afford the desired product (500 mg, 57%).


STEP 3.9

- 15 Scheme B, step j; A solution of the phthalimido lactam of Step 3.8 (500 mg, 0.979 mmol) in methanol (10 mL) is treated at ambient temperature with hydrazine hydrate (2.0 mL,

2.0 mmol, 1.0 M methanol). The reaction mixture is stirred 72 h and filtered through Celite. The filtrate is concentrated to a white solid (400 mg, 107%).


STEP 3.10

5




Scheme B, step k; A solution of the amine of Step 3.9 (400 mg, 1.05 mmol) and 2R-bromo-6-phthalimidocaproic acid (500 mg, 1.47 mmol) in dimethylformamide (5 mL) is treated sequentially with N-methylmorpholine (0.33 mL, 3.0 mmol), EDC (288 mg, 1.50 mmol), and HOBt (203 mg, 1.50 mmol). The reaction mixture is stirred at ambient temperature for 18 h and concentrated. The residue is partitioned between ethyl acetate (75 mL) and brine (15 mL), dried (Na₂SO₄) and concentrated. The crude product is purified by flash chromatography using ethyl acetate to afford the desired bromoamide as a foam (500 mg, 71%).


15

STEP 3.11


- 5 Scheme B, step i; A solution of bromoamide of Step 3.10 (500 mg, 0.714 mmol) and p-methoxybenzylmercaptan (0.35 mL, 2.5 mmol) in dimethylformamide (5 mL) is degassed (vacuum- N_2) and treated at ambient temperature with cesium carbonate (400 mg, 1.22 mmol). After 18 h, the orange suspension is concentrated, and the residue is partitioned between ethyl acetate (75 mL) and water (15 mL). The organic layer is dried (Na_2SO_4) and concentrated.
- 10 The crude product is purified by flash chromatography using ethyl acetate to afford the α -thioamide (326 mg, 59%).

STEP 3.12

Scheme B, step m; A mixture of α-thioamide of Step 3.11 (326 mg, 0.420 mmol),
5 mercuric acetate (234 mg, 0.734 mmol) and anisole (0.45 mL, 4.2 mmol) in methylene
chloride (12 mL) is cooled in an ice bath, degassed (vacuum-N₂) and treated with
trifluoroacetic acid (5 mL). After 3 h, H₂S gas is bubbled through the reaction mixture for 15
min. The black precipitate is filtered and washed with methylene chloride. The filtrate is
concentrated and residual trifluoroacetic acid is removed by coevaporation with carbon
10 tetrachloride. The residue is triturated with hexanes to yield the product mixture as a tan solid
(350 mg). This mixture is purified by reverse phase preparative HPLC using 30%
CH₃CN/water (0.1% tfa) as the eluent to give the desired product (130 mg, 47%).

EXAMPLE 4Preparation of Compound II-2

5


STEP 4.1

10

Scheme C, step a; Prepare by the method of Example 1, Step 1.1 using ethylamine to give the title compound.


STEP 4.1.1

-117-



Scheme C, step b; Prepare by the method of Example 1, Step 1.1.1 using the product of Example 4, step 4.1 to give the title compound.


5

STEP 4.2

Scheme A, step f; Prepare by the method of Example 1, step 1.3.5 using the product of Example 4, step 4.1.1 to provide the title compound.

10


STEP 4.3



Scheme A, step g; Prepare by the method of Example 1, step 1.3.6 using the product of Example 4, step 4.2 to provide the title *cis*- and *trans*- compounds.

5


STEP 4.4



Scheme A, step h1; Prepare by the method of Example 1, step 1.3.7 using the *cis*-isomer product of Example 4, step 4.3 to provide the title compound.


10

STEP 4.5



Scheme A, step 11; Prepare by the method of Example 1, step 1.3.8 using product of Example 4, step 4.4 to provide the title compound.


5

STEP 4.6

Scheme A, step j1; Prepare by the method of Example 1, step 1.3.9 using product of Example 4, step 4.5 to provide the title compound.

STEP 4.7

5





Scheme A, step k1; Prepare by the method of Example 1, step 1.3.10 using product of Example 4, step 4.6 to provide the title compound.

10


EXAMPLE 5

Preparation of Compound III-9

STEP 5.1


5

Scheme C, step a; Prepare by the method of Example 1, Step 1.1 using Boc-Val-OH to give the title compound.


STEP 5.1.1

10

Scheme C, step b; Prepare by the method of Example 1, Step 1.1.1 using the product of Example 5, step 5.1 to give the title compound.

STEP 5.2


Scheme A, step f; Prepare by the method of Example 1, step 1.3.5 using the product of
5 Example 5, step 5.1.1 to provide the title compound.

STEP 5.3

Scheme A, step g; Prepare by the method of Example 1, step 1.3.6 using the product of Example 5, step 5.2 to provide the title *cis*- and *trans*- compounds.

STEP 5.4


5



Scheme A, step h1; Prepare by the method of Example 1, step 1.3.7 using the *trans*-isomer product of Example 5, step 5.3 to provide the title compound.


10

STEP 5.5



Scheme A, step i1; Prepare by the method of Example 1, step 1.3.8 using product of Example 5, step 5.4 to provide the title compound.

STEP 5.6




5

Scheme A, step j1; Prepare by the method of Example 1, step 1.3.9 using product of Example 4, step 4.5 to provide the title compound.

STEP 5.7

10





Scheme A, step k1; Prepare by the method of Example 1, step 1.3.10 using product of Example 5, step 5.6 to provide the title compound.

5


EXAMPLE 6

Preparation of Compound IV-28



STEP 6.1


Scheme B, step k; Prepare by the method of Example 3, step 3.10 reacting the amine
5 product of Example 3, step 3.9 with 2-bromopentanoic acid to provide the title compound.

STEP 6.2

10

Scheme B, step l; Prepare by the method of Example 3, step 3.11 using the product of
Example 6, step 6.1 to provide the title compound.



15

STEP 6.3

Scheme B, step m; Prepare by the method of Example 3, step 3.12 using the product
5 of Example 6, step 6.2 to provide the title compound.


EXAMPLE 7Preparation of Compound II-37

10

STEP 7.1


Scheme A, step a; Prepare by the method of Example 1, step 1.3 using 4-methylcyclohexanone to provide the title compound.

5 STEP 7.2



10 Scheme A, step b; Prepare by the method of Example 1, step 1.3.1 using the product of Example 7, step 7.1 to provide the title compound.


STEP 7.3



15


Scheme A, step c; Prepare by the method of Example 1, step 1.3.2 using the product of Example 7, step 7.2 to provide the title compound.

STEP 7.4



Scheme A, step d; Prepare by the method of Example 1, step 1.3.3 using the product
5 of Example 7, step 7.3 to provide the title compound.

STEP 7.5




10

Scheme A, step e; Prepare by the method of Example 1, step 1.3.4 using the product
of Example 7, step 7.4 to provide the title compound.


STEP 7.6

15




Scheme A, step f; Prepare by the method of Example 1, step 1.3.5 using the product of Example 7, step 7.5 and the amine salt product of Example 1.1.1 to provide the title compound.

STEP 7.7




Scheme A, step g; Prepare by the method of Example 1, step 1.3.6 using the product of Example 7, step 7.6 to provide the *cis*- and *trans*- isomers of title compound.

5


STEP 7.8

10 Scheme A, step h1; Prepare by the method of Example 1, step 1.3.7 using the product of Example 7, step 7.7 to provide the title compound.

STEP 7.9


• 15

Scheme A, step i1; Prepare by the method of Example 1, step 1.3.8 using the product of Example 7, step 7.8 to provide the title compound.

STEP 7.10

5

Scheme A, step j1; Prepare by the method of Example 1, step 1.3.9 using the product of Example 7, step 7.9 to provide the title compound.

STEP 7.11

5 Scheme A, step k1; Prepare by the method of Example 1, step 1.3.10 using the product of Example 7, step 7.10 to provide the title compound.

10

15

In a further embodiment, the present invention provides a method of inhibiting matrix metalloproteinase (MMP) to a patient in need thereof comprising administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of formula (1).

5 As used herein, the term "patient" refers to warm-blooded animals or mammals, including guinea pigs, dogs, cats, rats, mice, hamsters, rabbits and primates, including humans. A patient is in need of treatment to inhibit MMP when it would be beneficial to the patient to reduce the physiological effect of active MMP. For example, a patient is in need of treatment to inhibit MMP when a patient is suffering from a disease state characterized by excessive
10 tissue disruption or tissue degradation, such as, but not limited to, a neoplastic disease state or cancer; rheumatoid arthritis; osteoarthritis; chronic inflammatory disorders, such as emphysema or chronic bronchitis; cardiovascular disorders, such as atherosclerosis; corneal ulceration; dental diseases, such as gingivitis or periodontal disease; and neurological disorders, such as multiple sclerosis.

15 The identification of those patients who are in need of treatment to inhibit MMP is well within the ability and knowledge of one skilled in the art. A clinician skilled in the art can readily identify, by the use of clinical tests, physical examination and medical/family history, those patients who are suffering from disease states characterized by excessive tissue
20 disruption or tissue degradation.

An "effective matrix metalloproteinase inhibiting amount" of a compound of formula (1) is an amount which is effective, upon single or multiple dose administration to the patient, in providing relief of symptoms associated with MMP and is thus effective in inhibiting
25 MMP-induced tissue disruption and/or MMP-induced tissue degradation. As used herein, "relief of symptoms" of MMP-mediated conditions refers to decrease in severity over that expected in the absence of treatment and does not necessarily indicate a total elimination or cure of the disease. Relief of symptoms is also intended to include prophylaxis.

30 An effective matrix metalloproteinase inhibiting dose can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the effective dose, a number of factors are considered including, but not limited to: the species of the patient; its size, age, and general health; the

specific disease involved; the degree of involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; and the use of concomitant medication.

5

An effective matrix metalloproteinase inhibiting amount of a compound of formula (1) will generally vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 300 milligrams per kilogram of body weight per day (mg/kg/day). A daily dose of from about 1 mg/kg to about 100 mg/kg is preferred.

10

The term "neoplastic disease state" as used herein refers to an abnormal state or condition characterized by rapidly proliferating cell growth or neoplasm. Neoplastic disease states for which treatment with a compound of formula (1) will be particularly useful include: Leukemias, such as, but not limited to, acute lymphoblastic, chronic lymphocytic, acute myeloblastic and chronic myelocytic; Carcinomas and adenocarcinomas, such as, but not limited to, those of the cervix, oesophagus, stomach, small intestines, colon, lungs (both small and large cell), breast and prostate; Sarcomas, such as, but not limited to, oesteroma, osteosarcoma, lipoma, liposarcoma, hemangioma and hemangiosarcoma; Melanomas, including amelanotic and melanotic; and mixed types of neoplasias such as, but not limited to carcinosarcoma, lymphoid tissue type, follicular reticulum, cell sarcoma and Hodgkin's Disease. Neoplastic disease states for which treatment with a compound of formula (1) will be particularly preferred include carcinomas and adenocarcinomas, particularly of the breast, prostate and lung.

25

Atherosclerosis is a disease state characterized by the development and growth of atherosclerotic lesions or plaque. The identification of those patients who are in need of treatment for atherosclerosis is well within the ability and knowledge of one of ordinary skill in the art. For example, individuals who are either suffering from clinically significant atherosclerosis or who are at risk of developing clinically significant atherosclerosis are patients in need of treatment for atherosclerosis. A clinician of ordinary skill in the art can readily determine, by the use of clinical tests, physical examination and medical/family history, if an individual is a patient in need of treatment for atherosclerosis.

30

The term "chronic inflammatory disease" refers to diseases or conditions characterized by persistent inflammation in the absence of an identifiable irritant or microbial pathogen.

Inflammatory diseases for which treatment with a compound of formula (1) will be

5 particularly useful include: emphysema, chronic bronchitis, asthma, chronic obstructive pulmonary disorder and chronic inflammation.

In effecting treatment of a patient, a compound of formula (1) can be administered in any form or mode which makes the compound bioavailable in effective amounts, including
10 oral and parenteral routes. For example, the compound can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, topically, intranasally, rectally, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the disease state to be treated, the stage of the disease, and other relevant circumstances.

15 Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co. (1990).

A compound of formula (1) can be administered in the form of pharmaceutical compositions or medicaments which are made by combining a compound of formula (1) with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are
20 determined by the chosen route of administration, and standard pharmaceutical practice.

The pharmaceutical compositions or medicaments are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or
25 excipients are well known in the art. The pharmaceutical composition may be adapted for oral or parenteral use and may be administered to the patient in the form of tablets, capsules, suppositories, solution, suspensions, gels, ointments, aerosol or the like.

The pharmaceutical compositions may be administered orally, for example, with an
30 inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, a compound of formula (1) may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations

should contain at least 4% of a compound of formula (1), the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the active ingredient present in compositions is such that a unit dosage form suitable for administration will be obtained.

5

The tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants: binders, such as microcrystalline cellulose, gum tragacanth or gelatin; excipients, such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants, such as magnesium stearate or Sterotex; glidants, such as colloidal silicon dioxide; and sweetening agents, such as sucrose or saccharin may be added or
10 flavoring agents, such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
15 Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active ingredient, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

20

For the purpose of parenteral administration, a compound of formula (1) may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the active ingredient present in such compositions is such that a suitable dosage will be obtained.

25

The solutions or suspensions may also include one or more of the following adjuvants depending on the solubility and other properties of a compound of formula (1): sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or
30 methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of toxicity such as sodium chloride or dextrose. The parenteral preparation

can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

EXAMPLE 8

5

Method for Characterization of MMP Inhibitors

A. Source and Activation of proMMP-3

ProMMP-3 (EC 3.4.24.17; Stromelysin-1) was purified from culture medium of human
10 rheumatoid synovial fibroblasts stimulated with macrophage-conditioned medium according
to Okada, Y. et al., J. Biol. Chem. 261, 14245-14255 (1986). The active MMP-3 was obtained
by treatment of proMMP-3 with trypsin (5 µg/mL) at 37°C for 30 min, followed by addition of
soybean trypsin inhibitor (50 µg/mL). Aliquots of the activated MMP-3 were stored at
-20°C.

15

B. Determination of Inhibition Constant (K_i) for MMP-3

The activated MMP-3 is assayed using a fluorogenic substrate, Mca-Pro-Leu-Gly-Leu-
Dpa-Ala-Arg-NH₂, Knight, C.G. et al., FEBS Lett. 296, 263-266 (1992), at 37°C in an assay
buffer containing 50 mM Tris, pH 7.6, 0.2 M NaCl, 50 mM CaCl₂, and 0.02% Brij-35. The
20 increase in fluorescence due to cleavage of Gly-Leu peptide bond by MMP-3 was monitored
with Perkin-Elmer LS50B Fluorimeter (λ_{ex} 328 nm, λ_{em} 393 nm, excitation slit 2.5, emission
slit 10). Substrate and inhibitor stock solutions were made in DMF and 0.1% HCl-DMF,
respectively. For determination of K_i values for MMP-3 inhibitors, a series of intermediate
inhibitor solutions were prepared in 0.1% HCl-DMF and 1 or 2 µL of the diluted inhibitor
25 solution was mixed with 1 µL of 2 mM substrate solution in DMF in a quartz cuvette
containing 2 mL of assay buffer. The enzyme (10 µL of 0.2 µM MMP-3 dilution in assay
buffer) was added at the last to start the reaction. For routine measurement of a K_i value for a
reversible, competitive inhibitor, the initial rates in the presence of at least four inhibitor
concentrations (two concentrations above K_i and two concentrations below K_i) were measured
30 using $[S] = 1 \mu M$ ($\ll K_m$) and $[MMP-3] = 1 nM$. Under these conditions, the measured $K_{i, app}$
is close to true K_i .

C. Source and Activation of proMMP-2

Recombinant MMP-2 was purified from the fermentation broth of yeast *Pichia pastoris* that carries the integrated MMP-2 gene into its chromosome. In brief, the full-length cDNA for MMP-2 was obtained by reverse transcription of RNA from human melanoma A375M cell line by the reverse transcriptase polymerase chain reaction (RT-PCR) using sequence specific oligonucleotides. The nucleotide sequence was confirmed by Taq cycle sequencing. The cDNA was ligated into the *Pichia pastoris* expression vector pHIL-D2 in such a way that the expression of pro-MMP2 is under the control of the methano inducible alcohol oxidase promoter. The expression construct was digested with either SalI or NsiI and used to transform the *Pichia pastoris* strains KM71 and SMD1168. A large-scale culture of a selected clone designated 24S was performed in a high cell density fermentor and the recombinant MMP-2 was purified from the culture supernatant by gelatin-sepharose 4B (Pharmacia). The enzyme is sufficiently pure at this stage for routine measurement of inhibition. If desired, however, the enzyme may be further purified by AcA 44 gel filtration (Spectra).

D. Determination of Inhibition Constant (K_i) for MMP-2

The active MMP-2 was obtained by activation of proMMP-2 at 37°C for 1 h with 4-aminophenylmercuric acetate which was then removed by a Sephadex G-50 spin column. The enzyme is assayed using a fluorogenic substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂, at 37°C in 2.0 mL of assay buffer containing 50 mM Tris, pH 7.6, 0.2 M NaCl, 50 mM CaCl₂, 0.02% Brij-35, and 50 μ M β -mercaptoethanol. The increase in fluorescence is monitored (λ_{ex} 328 nm, λ_{em} 393 nm). Substrate and inhibitor stock solutions are made in DMF. The enzyme is added at the last to start the reaction. For routine measurement of a K_i value for a reversible, competitive inhibitor, the initial rates in the presence of at least four inhibitor concentrations (two inhibitor concentrations above K_i and two below K_i) are measured using [S] = 1 μ M ($\ll K_m$) and [MMP-2] = 0.4 nM. Under these conditions, the measured $K_{i, app}$ is close to true K_i .

E. Source of MMP-12 (macrophage metalloelastase)

MMP-12 (EC 3.4.24.65) was cloned, expressed and purified according to Shapiro, S.D. et al., *J Biol. Chem.* 268, 23824-23829 (1993). Autoactivation resulted in the fully processed active form of the enzyme. Aliquots of MMP-12 were stored at -70°C.

F. Determination of the inhibition constant (K_i) for MMP-12.

The potency of inhibitors of MMP-12 was measured using either quartz cuvettes or microtiter plates. The activity of MMP-12 was measured using a fluorogenic substrate, Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂, Knight, C.G. et al., FEBS Lett. 296,263-266 (1992), at 25°C in an assay buffer containing 50 mM Tris, pH 7.6, 0.2 M NaCl, 50 mM CaCl₂, and 0.02% Brij-35. The increase in fluorescence due to cleavage of Gly-Leu peptide bond by MMP-12 was monitored with a Perkin-Elmer LS50B Fluorimeter (λ_{ex} 328 nm, λ_{em} 393 nm, excitation slit 2.5, emission slit 10) for the cuvette assay and with a Molecular Devices Fmax fluorescence plate reader (λ_{ex} 320 nm, λ_{em} 405 nm) for the microtiter plate assay. Substrate and inhibitor stock solutions were made in N,N-dimethylformamide (DMF) and 0.1% HCl-DMF, respectively.

K_i values were determined using the cuvette method by preparing a series of intermediate inhibitor solutions in 0.1% HCl-DMF and mixing the inhibitor with substrate (final concentration 2 μ M) in a quartz cuvette containing 2 ml of assay buffer. MMP-12 was added to start the reaction at a concentration of 2 nM and progress curves were generated. For routine measurement of a K_i value for a reversible competitive inhibitor, the initial rates in the presence of at least four inhibitor concentrations (two concentrations above and two concentrations below the K_i) were measured [S] = 2 μ M ($\ll K_m$) and [MMP-12] = 2 nM. Under these conditions, the measured $K_{i,app}$ is close to the true K_i .

K_i values were determined using the microtiter plate method in a manner similar to that described for the cuvette method with some modifications. Four different inhibitor concentrations (50 μ l in assay buffer) of each compound were added to separate wells of a microtiter plate and substrate was added (100 μ l) to get a final concentration of 4 μ M. MMP-12 was added to a final concentration of 2 nM (50 μ l) to start the reaction. Cleavage of substrate was recorded every 30 seconds for 30 minutes and progress curves were generated.

G. Calculation of K_i Values

The K_i for a competitive inhibitor is calculated using: $v_0/v_i = (1 + [I]/K_{i,app})$ and $K_i = K_{i,app}/(1 + [S]/K_m)$, where v_0 is the initial rate in the absence of inhibitor, v_i is the initial rate in

the presence of inhibitor at the concentration of [I], [S] is the substrate concentration, and K_m is the Michaelis constant. If slow binding is observed (i.e. if the approach to the binding equilibrium is slow), the final steady-state rate rather than the initial rate is taken as v_i .

TABLE 4

Compound	MMP-2 (K_i , nm)	MMP-3 (K_i , nm)	MMP-12 (K_i , nm)
II-1	1.2	39	18
III-1	N.T.*	73	53
IV-1	N.T.	210	N.T.

*N.T. = not tested

The compounds of formula (1) can be tested by any appropriate model for *in vivo* drug absorption. The *in vivo* absorption of a compound of formula (1) can be confirmed using an *in situ* rat intestinal technique as described by Blanchard, J. et al., Journal of Pharmaceutical Sciences, 79, 411-414 (1990). In this technique, the absorption of a compound of formula (1) is evaluated using this *in situ* rat intestinal perfusion technique in which the disappearance from the intestinal lumen, binding to the perfused jejunal segment, and appearance in the mesenteric (jejunal) vein are measured.


Likewise, the ability of compounds of formula (1) to inhibit matrix metalloproteinase *in vivo* can be tested by any appropriate model for *in vivo* inhibition of matrix metalloproteinase. The *in vivo* inhibition of matrix metalloproteinase, as well as the anti-tumoral effects of the compounds of formula (1), can be confirmed using a technique described by Davies, B. et al., Cancer Research 53, 2087-2091 (1993) where human ovarian xenografts are grown in nude mice. Inhibition of the enzyme is demonstrated by the transition of ascites to solid tumors, concomitantly slowing tumor cell growth and allowing development of tumor stroma.

Similarly, the *in vivo* inhibition of matrix metalloproteinase by the compounds of formula (1) can be determined by injecting activated matrix metalloproteinase along with proteoglycan monomer (Lark, M.W. et al., Biochem Pharmacol. 39, 2041-2049 (1990)) or ^3H carboxymethyl transferrin (Chapman, K.T. et al, Bioorg. Med. Chem. Lett. 6, 803-806 (1996))

into the pleural cavity of mice or rats and measuring substrate degradation in the pleural fluid. The *in vivo* inhibition of cartilage degradation can be demonstrated using the adjuvant induced arthritis model (Conway, J.G. et al., J. Exp. Med. 182, 449-457) or any of a number of animal models of arthritis.

WHAT IS CLAIMED IS:


1. A compound of the formula




wherein

- R_1 is C_1 - C_6 alkyl, a $W-(CH_2)_m$ group, or a $Q-Z-(CH_2)_m$ group wherein W is phthalimido; Z is a bond or is oxy, NR_6 , $C(O)NR_6$, $NR_6C(O)$, $NHC(O)NR_6$, $OC(O)NR_6$, $HNC(O)O$, or SO_2NR_6 ; Q is hydrogen, or a $Y-(CH_2)_n$ group wherein Y is hydrogen, C_6 - C_{10} aryl, C_3 - C_9 heteroaryl, $-C(O)OR_6$, $-N(R_6)_2$, morpholino, piperidino, pyrrolidino, or isoindolyl;
- R_2 is C_1 - C_4 alkyl, a $-(CH_2)_p$ - $(C_3$ - $C_9)$ heteroaryl group, or a $-(CH_2)_p$ - Ar_1 group wherein Ar_1 is phenyl or naphthyl optionally substituted with a substituent selected from the group consisting of halogen, C_1 - C_4 alkyl, $-OR_7$, $-N(R_6)_2$, $SO_2N(R_6)_2$ or $-NO_2$;
- R_3 is hydrogen, C_1 - C_6 alkyl, $-CH_2SCH_2NHCOCH_3$, a $-(CH_2)_p$ - A group, a $-(CH_2)_m$ - B group or a $-CH_2$ - D - R_7 group wherein A is C_6 - C_{10} aryl, C_3 - C_9 heteroaryl, or cyclohexyl; B is $-N(R_7)_2$, guanidino, nitroguanidino, $-C(O)OR_6$ or $-C(O)NR_6$; and D is oxy or thio;
- R_4 is hydrogen or a $-(CH_2)_m$ - $S(O)_pX'(R_6)_2$ group;
- R_5 is hydrogen, C_1 - C_6 alkyl or R_4 and R_5 taken together with the nitrogen atom to which they are attached form piperidino, pyrrolidino, or isoindolyl;
- R_6 is hydrogen or C_1 - C_6 alkyl;
- R_7 is hydrogen, C_1 - C_4 alkyl, or a $-(CH_2)_p$ - Ar_2 group wherein Ar_2 is phenyl or naphthyl optionally substituted with a substituent selected from the group consisting of halogen, C_1 - C_4 alkyl, $-OR_7$, $-N(R_6)_2$, $SO_2N(R_6)_2$ or $-NO_2$;
- R_8 is hydrogen, $-C(O)R_7$, a $-C(O)-(CH_2)_q$ - K group or a $-S$ - G group, wherein K is selected from the group consisting of

-144-



G is selected from the group consisting of



- 5 R_9 and R_{10} are each independently C_1 - C_4 alkyl or a $-(CH_2)_p-Ar_2$ group;
 R_{11} is $-CF_3$, C_1 - C_{10} alkyl or a $-(CH_2)_p-Ar_2$ group;












- R_{12} is hydrogen, C_1 - C_6 alkyl, $-CH_2CH_2S(O)_pCH_3$, or arylalkyl;
 R_{13} is hydrogen, hydroxy, amino, C_1 - C_6 alkyl, N-methylamino, N,N-dimethylamino, $-CO_2R_{17}$ or $-OC(O)R_{18}$ wherein R_{17} is hydrogen, $-CH_2O-C(O)C(CH_3)_3$, C_1 - C_4 alkyl, a $-(CH_2)_p-Ar_2$ group or diphenylmethyl and R_{18} is hydrogen, C_1 - C_6 alkyl or phenyl;
 5 R_{14} is 1 or 2 substituents independently chosen from the group consisting of hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, or halogen;
 R_{15} is hydrogen, C_1 - C_6 alkyl or a $-(CH_2)_p-Ar_2$ group;
 R_{16} is hydrogen or C_1 - C_4 alkyl;
 V_1 is O, S, or NH;
 10 V_2 is N or CH;
 V_3 is a bond or $-C(O)-$;
 V_4 is $-(CH_2)_w-$, O, S, NR_7 , or $NC(O)R_{11}$;
 X and X' are each independently CH or N;
 m is an integer 2-4;
 15 n is zero or an integer 1-4;
 p is zero or an integer 1-2;
 q is zero or an integer 1-5;
 t is an integer 1-2;
 w is an integer 1-3; and
 20 w' is zero or an integer 1; or
 a pharmaceutically acceptable salt, stereoisomer or hydrate thereof.

2. A compound of claim 1 wherein X is CH.

25 3. A compound of claim 2 wherein R_2 is C_1 - C_4 alkyl or a $-(CH_2)_p-Ar$ group wherein Ar is phenyl optionally substituted with F, Cl, C_1 - C_4 alkyl, $-NO_2$, $-NH_2$ or $-OR_7$; and R_4 is hydrogen.

4. A compound of claim 3 wherein R_3 is hydrogen, C_1 - C_6 alkyl, phenyl, benzyl, 1-naphthyl, 2-naphthyl, cyclohexylmethyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 3,4-dihydroxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-bromophenyl, 3,4-dibromophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3-tolyl, 4-tolyl, 4-

ethylphenyl, 4-isopropylphenyl, 3-aminophenyl, 4-aminophenyl, 3,4-diaminophenyl, N-methyl-4-aminophenyl, 2-nitrophenyl, 4-nitrophenyl, 4-aminobenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-bromobenzyl, 4-methylbenzyl, $-\text{CH}_2\text{SCH}_2\text{NHCOCH}_3$, or is a compound of the formula



5. A compound of claim 4 wherein R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl and R_8 is hydrogen.

6. A compound of claim 2 wherein R_1 is a $W-(\text{CH}_2)_m$ - group.

7. A compound of claim 3 wherein R_1 is a $W-(\text{CH}_2)_m$ - group.

8. A compound of claim 5 wherein R_1 is a $W-(\text{CH}_2)_m$ - group.

9. A compound of claim 2 wherein R_1 is C_1 - C_6 alkyl.

10. A compound of claim 3 wherein R_1 is C_1 - C_6 alkyl.

11. A compound of claim 5 wherein R_1 is a C_1 - C_6 alkyl.

12. A compound of claim 2 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

5

13. A compound of claim 3 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

14. A compound of claim 5 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

10


15. A compound of claim 1 wherein X is N.

16. A compound of claim 15 wherein R_2 is C_1 - C_4 alkyl or a $-(CH_2)_p$ -Ar group wherein Ar is phenyl optionally substituted with F, Cl, C_1 - C_4 alkyl, $-NO_2$, $-NH_2$ or $-OR_8$; and R_4 is hydrogen.

15

17. A compound of claim 16 wherein R_3 is hydrogen, C_1 - C_6 alkyl, phenyl, benzyl, 1-naphthyl, 2-naphthyl, cyclohexylmethyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 3,4-dihydroxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-bromophenyl, 3,4-dibromophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3-tolyl, 4-tolyl, 4-ethylphenyl, 4-isopropylphenyl, 3-aminophenyl, 4-aminophenyl, 3,4-diaminophenyl, N-methyl-4-aminophenyl, 2-nitrophenyl, 4-nitrophenyl, 4-aminobenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, 3-chlorobenzyl, 4-fluorobenzyl, 3,4-dichlorobenzyl, 4-bromobenzyl, 4-methylbenzyl, $-CH_2SCH_2NHCOCH_3$, or is a compound of the formula

20



18. A compound of claim 17 wherein R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl and R_8 is hydrogen.

19. A compound of claim 16 wherein R_1 is a $W-(CH_2)_m$ - group.

20. A compound of claim 17 wherein R_1 is a $W-(CH_2)_m$ - group.

21. A compound of claim 19 wherein R_1 is a $W-(CH_2)_m$ - group.

22. A compound of claim 16 wherein R_1 is C_1 - C_6 alkyl.

23. A compound of claim 17 wherein R_1 is C_1 - C_6 alkyl.

24. A compound of claim 19 wherein R_1 is a C_1 - C_6 alkyl.

25. A compound of claim 16 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

26. A compound of claim 17 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

27. A compound of claim 19 wherein R_1 is a $Q-Z-(CH_2)_m$ - group.

5

28. A compound of claim 1 wherein X is CH; R_2 is phenyl, methyl or ethyl; R_3 is phenyl, benzyl, cyclohexylmethyl, isopropyl, isobutyl, 3-pyridylmethyl, 4-fluorobenzyl or 4-aminobenzyl; R_4 is hydrogen; R_5 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl or isobutyl and R_8 is hydrogen.

10

29. A compound of claim 28 wherein R_1 is a $W-(CH_2)_m$ - group.

30. A compound of claim 1 wherein X is N; R_2 is phenyl, methyl or ethyl; R_3 is phenyl, benzyl, cyclohexylmethyl, isopropyl, isobutyl, 3-pyridylmethyl, 4-fluorobenzyl or 4-aminobenzyl; R_4 is hydrogen; R_5 is hydrogen, methyl, ethyl, , propyl, isopropyl, butyl or isobutyl and R_8 is hydrogen.

15

31. A compound of claim 30 wherein R_1 is a $W-(CH_2)_m$ - group.

20

32. A compound of claim 1 wherein said compound is 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-5-phenyl-1*H*-azepin-3-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [3*S*-[1(*R**), 3 α , 5 α]]-.

33. A compound of claim 1 wherein said compound is 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-5-phenyl-1*H*-azepin-3-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [3*S*-[1(*R**), 3 α , 5 β]]-.

25

34. A compound of claim 1 wherein said compound is 2*H*-Isoindole-2-hexanamide, *N*-[hexahydro-4-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-5-oxo-1-(phenylmethyl)-1*H*-1,4-diazepin-6-yl]-1,3-dihydro- α -mercapto-1,3-dioxo-, [6*S*-[4(*R**), 6*R**(*R**)]]-.

30

35. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

36. A method of inhibiting matrix metalloproteinase in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

5

37. A method of inhibiting MMP-induced tissue disruption and/or MMP-induced tissue degradation in a patient in need thereof which comprises administering to the patient and effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

10

38. A method of treating rheumatoid arthritis in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

15

39. A method of treating osteoarthritis in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

20

40. A method of treating a chronic inflammatory disorder in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

25

41. A method of treating a neoplastic disease state in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

42. A method of treating a cardiovascular disorder in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

30

43. A method of claim 42 wherein said cardiovascular disorder is atherosclerosis.

44. A method of treating corneal ulceration in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

5 45. A method of treating gingivitis or periodontal disease in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

10 46. A method of treating multiple sclerosis in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

15 47. A method of treating chronic obstructive pulmonary disorder in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

AMENDED CLAIMS

[received by the International Bureau on 17 February 1998 (17.02.98);
new claims 48-59 added; remaining claims unchanged (2 pages)]

44. A method of treating corneal ulceration in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

5 45. A method of treating gingivitis or periodontal disease in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

10 46. A method of treating multiple sclerosis in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

15 47. A method of treating chronic obstructive pulmonary disorder in a patient in need thereof which comprises administering to the patient an effective matrix metalloproteinase inhibiting amount of a compound of claim 1.

20 48. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for inhibiting matrix metalloproteinase.

 49. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for inhibiting MMP-induced tissue disruption and/or MMP-induced tissue degradation.

25 50. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating rheumatoid arthritis.

30 51. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating osteoarthritis.

- 153 -

52. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating a chronic inflammatory disorder.

5 53. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating a neoplastic disease state.

10 54. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating a cardiovascular disorder.

15 55. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating corneal ulceration.

20 56. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating gingivitis or periodontal disease.

57. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating multiple sclerosis.

25 58. The use of a compound of Claim 1, optionally in combination with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treating chronic obstructive pulmonary disorder.

59. The use of a compound of Claim 1 as a pharmaceutically active compound.

30

INTERNATIONAL SEARCH REPORT

In' Application No

PCT/US 97/13738

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K5/078 A61K38/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 88 06890 A (RES CORP TECHNOLOGIES INC) 22 September 1988 see the whole document ---	1-47
Y	WO 96 11209 A (CHIROSCIENCE LTD) 18 April 1996 see the whole document ---	1-47
Y	DATABASE WPI Section Ch, Week 9604 Derwent Publications Ltd., London, GB; Class B02, AN 96-035866 XP002046217 & JP 07 304 746 A (KANEBO LTD) , 21 November 1995 see abstract --- -/--	1-47



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 November 1997

Date of mailing of the international search report

17.12.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/13738

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BURKHOLDER E.A.: "The synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained gauche (-) dipeptide mimetics" BIOORG.MED.CHEM.LETT., vol. 3, no. 2, 1993, pages 231-234, XP002046216 see the whole document ---	1-47
Y,P	WO 96 29313 A (PROCTER & GAMBLE) 26 September 1996 see the whole document -----	1-47

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/13738

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/13738

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 36-47 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In: Application No

PCT/US 97/13738

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8806890 A	22-09-88	AT 106087 T	15-06-94
		DE 3889726 D	30-06-94
		DE 3889726 T	13-10-94
		EP 0358660 A	21-03-90
		JP 2502537 T	16-08-90
		JP 2586942 B	05-03-97

WO 9611209 A	18-04-96	AU 3612795 A	02-05-96
		EP 0784629 A	23-07-97
		FI 971412 A	04-04-97
		NO 971537 A	04-06-97
		PL 319503 A	18-08-97

WO 9629313 A	26-09-96	US 5672598 A	30-09-97
		AU 5255896 A	08-10-96
